Investigating excitatory GABAergic signalling & benzodiazepine resistance in an
in vitro model of status epilepticus

Richard J. Burman
BRMRIC001

A thesis presented for the degree of
Masters of Medical Science in Medical Biochemistry

Supervisor:
Dr Joseph V. Raimondo
Department of Human Biology

Co-supervisor:
Professor Arieh A. Katz
Department of Integrated Biomedical Sciences

November 2017
The copyright of this thesis vests in the author. No quotation from it or information derived from it is to be published without full acknowledgement of the source. The thesis is to be used for private study or non-commercial research purposes only.

Published by the University of Cape Town (UCT) in terms of the non-exclusive license granted to UCT by the author.
Plagiarism declaration

I, Richard Joseph Burman, hereby declare that the work in this thesis is my original work (except where acknowledgements indicate otherwise). I know what plagiarism entails and that it is a punishable offence because it constitutes theft. I understand the plagiarism policy of the University of Cape Town and the consequences if I am seen to plagiarise any part of this thesis.

I declare, therefore, that all work presented by me in this thesis is my own, and where I have made use of another’s work, I have referenced accordingly using the Harvard referencing convention.

Signed by candidate

signature removed

3 November 2017

Signature

Date
Abstract

Status epilepticus (SE) describes a state of persistent seizures which are unrelenting. First-line treatment for status epilepticus uses a group of drugs, the benzodiazepines, that promote the action of the major inhibitory neurotransmitter within the brain, gamma (γ)-aminobutyric acid (GABA). In a subset of patients however, benzodiazepines prove to be ineffective in terminating SE.

Previous data from *in vitro* models has demonstrated that during single seizures, instead of being inhibitory, activation of the GABA\textsubscript{A} receptor can have an excitatory effect on neurons. To date, it is unknown whether this shift in GABAergic function contributes to SE, nor how it may modulate the anticonvulsant properties of benzodiazepines. In this thesis I explore the role of excitatory GABAergic signaling in an *in vitro* model of SE and how this may affect the anticonvulsant efficacy of the benzodiazepine, diazepam.

Firstly, I confirm that benzodiazepine-resistant SE is prevalent in a South African paediatric population. Secondly, consistent with its established mechanism of action, I show that diazepam enhances GABA\textsubscript{A}R synaptic currents. Thirdly, using the *in vitro* 0 Mg\textsuperscript{2+} model of status epilepticus I show that whilst early application of diazepam has anticonvulsant properties, this is lost when the drug is applied during prolonged epileptiform activity. Fourthly, to investigate this phenomenon I use optogenetic activation of GABAergic interneurons to show that interneurons can drive epileptiform discharges during SE-like activity *in vitro*. Finally, I confirm that during seizure-like events there is a transient shift in GABAergic signaling that is caused by activity driven changes in the transmembrane Cl\textsuperscript{−} gradient.

This thesis provides insight into how excitatory GABAergic signaling during prolonged seizures may contribute towards benzodiazepine resistance in SE. I believe that these results are relevant for understanding of the pathophysiology of SE and may help inform optimal treatment protocols for this condition.
Acknowledgements

To my supervisor, Joe Raimondo, you have been incredible. Thank you for sharing your passion for neuroscience with me, for always having an open door and above all, for believing in me. You have enriched my life in so many wonderful ways and through it all you have been a constant source of inspiration. Thank you.

To my co-supervisor, Arieh Katz, thank you for your selfless work in creating a platform for medical students to engage with science. Your dedication to students is unparalleled.

To my mentors, Jo Wilmshurst and Graham Fiegen, thank you for being so generous with your time and for always being there to support me.

To Andy Trevelyan and Colin Akerman, thank you for your invaluable input into this project over the years.

To my fellow Raimondo Lab minions, thank you for always making the lab such a happy place.

To Hayley, it has been such a privilege sharing this adventure with you right from the start. Thank you for being the loving person that you are.

To my dear friends, thank you all for being such wonderful cheerleaders.

To my clinical partner, Dave, thank you for your patience and for always having my back. It has been a pleasure spending my clinical years with you.

Für meine liebe Anna. Auch wenn du erst gegen Ende zu mir gestossen bist, warst du umso wichtiger, um mich über diese Ziellinie zu bringen.

And finally to my beloved family. Mum, Dad and Greg, you have each played such a significant part in this journey. None of what I have been able to achieve would have been possible without you. I love you all very much.
Mum,

I dedicate this to you.
1 Introduction 7

1.1 GABAergic signalling: the principal player in fast synaptic inhibition 7

1.1.1 Normal neuronal signalling: a balance between excitation and inhibition 7

1.1.2 The inhibitory network 8

1.1.3 Fast synaptic inhibition is mediated by the GABA\textsubscript{A} receptor 9

1.1.4 The benzodiazepines: a class of GABA\textsubscript{A}R allosteric modulator 12

1.2 Chloride dynamics in the brain 13

1.2.1 Establishing the transmembrane chloride gradient in mature neural tissue 13

1.2.2 The state of the Cl\textsuperscript{-} gradient determines the nature of GABA\textsubscript{A}R function 13

1.2.3 Studying GABA\textsubscript{A}R signalling & Cl\textsuperscript{-} dynamics 15

1.2.4 Differential expression of CCCs causes long-term plasticity at the GABA synapse 17

1.2.5 Activity-driven Cl\textsuperscript{-} plasticity 19

1.3 Alterations in Cl\textsuperscript{-} dynamics and GABA\textsubscript{A}R signalling during seizures 22

1.3.1 Seizures: unregulated hypersynchronous hyperexcitability 22

1.3.2 Epilepsy: a global health burden 23

1.3.3 In vitro models of epileptic seizures 23

1.3.4 Endogenous anticonvulsant mechanisms 24

1.4 The relevance of excitatory GABAergic signalling in seizure activity 25
1.4.1 Depolarising GABAergic signalling within the ictal focus is caused by changes in the expression of cation-chloride co-transporters. ...

1.4.2 Transient Cl\(^{-}\) loading occurs during seizure activity. ...

1.4.3 Implications of depolarising GABA\(_R\) function on seizure dynamics. ...

1.5 Status epilepticus & benzodiazepine resistance. ...

1.5.1 Unremitting & self-perpetuating seizure activity. ...

1.5.2 Benzodiazepine resistance in status epilepticus. ...

1.5.3 Changes in GABA\(_R\) signalling during status epilepticus. ...

1.6 Aims & Objectives. ...

1.6.1 Objectives. ...

2 Materials and Methods ...

2.1 Clinical data. ...

2.1.1 Study design. ...

2.2 Tissue preparation. ...

2.2.1 Animal tissue. ...

2.2.2 Organotypic brain slice cultures. ...

2.2.3 Acute brain slices. ...

2.2.4 Viral transfection. ...

2.3 Imaging. ...

2.4 Intracellular recordings. ...

2.4.1 Cell visualisation. ...

2.4.2 Whole-cell recordings. ...

2.4.3 Perforated patch-clamp recordings. ...

2.4.4 Calculating GABA\(_R\) parameters. ...

2.5 Extracellular recordings. ...

2.5.1 Local field potentials. ...

2.6 Seizure models. ...

2.6.1 The 0 Mg\(^{2+}\) chemo-convulsant model. ...

2.6.2 Definitions of in vitro seizure activity. ...
3 Results

3.1 Benzodiazepine-resistant status epilepticus is prevalent in a South African paediatric cohort ........................................ 49

3.2 Diazepam enhances GABA\(_{\alpha}\)R mediated signaling .................. 52

3.2.1 Diazepam enhances the decay time constant, but not the amplitude of light-induced GABA\(_{\alpha}\)R synaptic currents in organotypic brain slices .......... 54

3.2.2 Diazepam enhances both the amplitude and the decay time constant of GABA\(_{\alpha}\)R synaptic currents in acute brain slices .................. 56

3.3 0 Mg\(^{2+}\) is a reliable in vitro model of status epilepticus .......... 59

3.3.1 The 0 Mg\(^{2+}\) model elicits prolonged seizure states in both organotypic and acute brain slices ............... 59

3.4 Differential effect of diazepam on the 0 Mg\(^{2+}\) in vitro model of status epilepticus ............................................. 62

3.4.1 Early application of diazepam has a significant anticonvulsant effect while late application augments bursting activity in the LRD phase ............................................. 63

3.5 GABAergic signalling is strongly depolarising during the late recurrent discharge phase .......................................... 69

3.5.1 Optogenetic activation of interneurons drives excitatory signalling in the evolution of prolonged seizure states .......... 69

3.5.2 Prolonged seizure activity leads to a significant decrease in light-induced GABAergic conductances .................. 71

3.6 Synchronised activation of GAD2 interneurons entrains network activity during the LRD phase through GABA\(_{\alpha}\)R signalling ................. 77

3.6.1 Synchronised activation of GAD2 interneurons is responsible for entraining the hippocampal network during the LRD phase .......... 79

3.7 Blocking the GABA\(_{\alpha}\)R reverses network entrainment via optogenetic activation of GAD2 interneurons ....................... 81

3.7.1 The frequency of epileptiform discharges during the LRD phase is affected by synchronised activation of GAD2 interneurons .......... 83

3.8 Studying activity-driven changes in intracellular Cl\(^{-}\) concentration .. 85
3.8.1 Both endogenous and exogenous GABA application can be used to determine the intracellular concentration of Cl\textsuperscript- in organotypic brain slices. 

3.8.2 Transient, activity-driven changes in intracellular Cl\textsuperscript- occur during single seizure-like events.

4 Discussion

4.1 Benzodiazepine-resistant status epilepticus is prevalent within our local paediatric population.

4.2 Diazepam modulates GABA\textsubscript{A}R synaptic currents during normal network activity.

4.3 The 0 Mg\textsuperscript{2+} model provides a reliable \textit{in vitro} replica of status epilepticus.

4.4 Diazepam has a differential and time-dependent effect on \textit{in vitro} status epilepticus.

4.5 GABAergic signalling drives epileptiform discharges during \textit{in vitro} status epilepticus.

4.5.1 GABAergic signalling is excitatory in both single seizures and SE-like activity.

4.5.2 GABAergic signalling is reduced after prolonged seizure activity.

4.5.3 Photoactivation of GABAergic signalling entrains SE-like activity through the GABA\textsubscript{A}R.

4.6 Seizure-induced changes in Cl\textsuperscript-. Using optogenetics to elicit GABAergic inhibitory signalling.

4.6.1 Transient, activity-driven changes in intracellular Cl\textsuperscript- during single-seizures.

4.7 General discussion.

4.8 Concluding remarks.

Bibliography

A Appendix

A.1 Protocols for treating paediatric status epilepticus.
### List of Figures

<table>
<thead>
<tr>
<th>Figure</th>
<th>Description</th>
<th>Page</th>
</tr>
</thead>
<tbody>
<tr>
<td>1.1</td>
<td>The GABA&lt;sub&gt;AR&lt;/sub&gt; is selectively permeable to Cl&lt;sup&gt;-&lt;/sup&gt; and HCO&lt;sub&gt;3&lt;/sub&gt;-</td>
<td>10</td>
</tr>
<tr>
<td>1.2</td>
<td>Cation-chloride co-transporters set the transmembrane chloride gradient</td>
<td>17</td>
</tr>
<tr>
<td>1.3</td>
<td>Activity-driven ionic plasticity precipitates a transient excitatory shift in GABA&lt;sub&gt;AR&lt;/sub&gt;-mediated signalling</td>
<td>20</td>
</tr>
<tr>
<td>1.4</td>
<td>Cl&lt;sup&gt;-&lt;/sup&gt; dynamics during seizure activity</td>
<td>28</td>
</tr>
<tr>
<td>2.1</td>
<td>Using optogenetics to activate endogenous GABAergic signalling</td>
<td>40</td>
</tr>
<tr>
<td>3.1</td>
<td>Local paediatric prevalence of benzodiazepine-resistant convulsive status epilepticus</td>
<td>51</td>
</tr>
<tr>
<td>3.2</td>
<td>Diazepam enhances the decay time constant but not the amplitude of light-induced GABA&lt;sub&gt;AR&lt;/sub&gt; currents in organotypic brain slices</td>
<td>54</td>
</tr>
<tr>
<td>3.3</td>
<td>Diazepam enhances the amplitude and decay time constant of GABA&lt;sub&gt;AR&lt;/sub&gt; currents in acute brain slices</td>
<td>57</td>
</tr>
<tr>
<td>3.4</td>
<td>The 0 Mg&lt;sup&gt;2+&lt;/sup&gt; in vitro model of status epilepticus</td>
<td>60</td>
</tr>
<tr>
<td>3.5</td>
<td>Differential effect of diazepam on the 0 Mg&lt;sup&gt;2+&lt;/sup&gt; model of status epilepticus in organotypic brain slices</td>
<td>65</td>
</tr>
<tr>
<td>3.6</td>
<td>Population data showing the differential effect of diazepam on the 0 Mg&lt;sup&gt;2+&lt;/sup&gt; model of status epilepticus in organotypic brain slices</td>
<td>67</td>
</tr>
<tr>
<td>3.7</td>
<td>Transient shifts in the effect of GABAergic interneurons during the evolution of prolonged seizure activity</td>
<td>71</td>
</tr>
<tr>
<td>3.8</td>
<td>Activation of GAD2 interneurons results in depolarising currents in pyramidal cells during single and prolonged seizures</td>
<td>73</td>
</tr>
<tr>
<td>3.9</td>
<td>Changes in baseline GABAergic signalling before and after prolonged seizure activity</td>
<td>75</td>
</tr>
<tr>
<td>Figure</td>
<td>Description</td>
<td>Page</td>
</tr>
<tr>
<td>--------</td>
<td>-------------</td>
<td>------</td>
</tr>
<tr>
<td>3.10</td>
<td>Photoactivation of GAD2 interneurons significantly increases discharge probability in the LRD phase</td>
<td>78</td>
</tr>
<tr>
<td>3.11</td>
<td>Network entrainment follows optogenetic photoactivation of GAD2 interneurons during the LRD phase</td>
<td>79</td>
</tr>
<tr>
<td>3.12</td>
<td>The GABAAR antagonist, picrotoxin, decreased network entrainment by photoactivation of GAD2 interneurons</td>
<td>81</td>
</tr>
<tr>
<td>3.13</td>
<td>Synchronised photoactivation of GAD2 interneurons and blocking of the GABAAR affects epileptiform discharge frequency during the LRD phase</td>
<td>84</td>
</tr>
<tr>
<td>3.14</td>
<td>Exogenous application of GABA versus optogenetic stimulated GAD2-interneurons to determine intracellular concentration of Cl⁻ in organotypic brain slices</td>
<td>86</td>
</tr>
<tr>
<td>3.15</td>
<td>Transient Cl⁻ loading occurs during a single seizure-like event</td>
<td>89</td>
</tr>
<tr>
<td>4.1</td>
<td>Disruptions to GABAAR structure and function may be responsible for benzodiazepine-resistant status epilepticus</td>
<td>104</td>
</tr>
</tbody>
</table>
Chapter 1

Introduction

1.1 GABAergic signalling: the principal player in fast synaptic inhibition

1.1.1 Normal neuronal signalling: a balance between excitation and inhibition

The sophisticated processing ability of the brain depends on the coordinated electrical activity of neurons. Communication between neurons is made possible by a tightly regulated ionic environment that produces the necessary electrochemical gradients to facilitate synaptic signalling (Johnston and Wu [1995]).
Communication between different brain cells largely, but not exclusively, occurs at
the synaptic junction \(\text{Shepherd} \ 2003\). Here, the interaction between neurotransmitters
and their specific receptors directs the flow of electrical charge. These seceptors on
the postsynaptic membrane are linked to specific ion channels. When activated, these
channels open and permit a movement of charge that causes both positive and negative
shifts in the neuronal membrane potential.

Signals that precipitate membrane depolarisation, bringing it closer to the action
potential threshold, are termed excitatory. These are matched by inhibitory synaptic
inputs that cause membrane hyperpolarisation and thereby impede action potential
generation. A broad equilibrium between excitation and inhibition is critical to produce
the asynchronous firing patterns that underlie normal network function. However, under
certain conditions this state can can be disrupted. The consequence of this is either
uncontrolled excitation or prolonged inactivity, which are both dysfunctional.

1.1.2 The inhibitory network

The stability of neural networks is maintained by the inhibitory action of neurons
loosely termed inhibitory interneurons \(\text{Markram et al.,} \ 2004\). The essential role
of inhibitory interneurons is evident in both their diversity and strategic positioning
throughout the brain. There is a large variety of these cells, each type with their own
morphology, firing pattern and distribution of synaptic contacts onto pyramidal cells.

At inhibitory synapses, inhibition is mediated by the presynaptic release of one of
two neurotransmitters: gamma (\(\gamma\))-amino butyric acid (GABA) or glycine \(\text{Bowery and}
\text{Smart} \ 2006\). GABA is the principal neurotransmitter which mediates fast synaptic
inhibition within the mature central nervous system (CNS) and will be the focus of my
thesis \(\text{Krnjević} \ 1974\).
1.1.3 Fast synaptic inhibition is mediated by the GABA<sub>A</sub> receptor

GABA is produced within the presynaptic terminal of what are referred to as GABAergic interneurons, the major class of inhibitory interneurons. Interestingly, GABA’s biosynthesis originates from the principal excitatory neurotransmitter, glutamate, a reaction catalysed by the enzyme glutamate decarboxylase (Bak et al., 2006). The inhibitory effects of GABA are generated through its binding to either GABA<sub>A</sub>, GABA<sub>B</sub> or GABA<sub>C</sub> receptors (GABA<sub>A</sub>Rs, GABA<sub>B</sub>Rs and GABA<sub>C</sub>Rs) (Bormann, 2000). The distribution of these different GABA receptors is responsible for synaptic inhibition across various spatial and temporal contexts. Here I will specifically focus on the role of the GABA<sub>A</sub>R in fast synaptic inhibition.

The GABA<sub>A</sub>R is a ligand-activated, ionotropic receptor (Olsen and Sieghart, 2009). It is largely, but not exclusively, expressed on the postsynaptic membrane. Its structure consists of a pentameric channel that is formed by different permutations of constitutive subunits. The different subunits are separated into classes according to their varied amino acid composition (α, β, γ, δ, ε, π, θ). Furthermore, some of these can be sub-classified into different isoforms (α<sub>1</sub>-6, β<sub>1</sub>-3, γ<sub>1</sub>-3). It is the multiplicity of subunit classes and isoforms that ultimately determines the biophysical properties of the channel including its ligand binding capacity and conductance. The most commonly expressed form of GABA<sub>A</sub>R pentamer includes the following combination: α<sub>1</sub>-β<sub>2</sub>-γ<sub>2</sub>-α<sub>1</sub>-β<sub>2</sub>. This is further illustrated in Figure 1.1.

The GABA<sub>A</sub>R is activated by the binding of GABA at sites located between the α<sub>1</sub> and β<sub>2</sub> subunits. This induces a conformational change in the pentameric channel to make it selectively permeable to Cl⁻ influx and, to a lesser extent, bicarbonate (HCO₃⁻) efflux (Kaila and Voipio, 1987; Kaila, 1994). Cl⁻ and HCO₃⁻ efflux occur at the same time at an estimated ratio of 4:1 (Kaila and Voipio, 1987; Kaila et al., 1989; Kaila...
However, Cl\(^-\) is predominant and because Cl\(^-\) moves down its transmembrane electrochemical gradient, under typical conditions there is an inward movement of negative charge. This hyperpolarises the neuronal membrane and is referred to as an inhibitory postsynaptic potential (IPSP).

The function of the GABA\(_A\)R can be enhanced or impeded using various pharmacological manipulations (Krogsgaard-Larsen et al., 1994; Olsen and Sieghart, 2009). GABA\(_A\)Rs can be activated by agonists such as isoguvacine and muscimol. GABA\(_A\)R function can also be blocked by antagonists such as bicucullin and picrotoxin. Furthermore, there are a growing selection of GABA\(_A\)R positive allosteric modulators, such as the benzodiazepines, that are able to enhance the GABA\(_A\)R conductance.

**Figure 1.1 (following page):** The GABA\(_A\)R is selectively permeable to Cl\(^-\) and HCO\(_3^-\). A, The GABA\(_A\)R is a pentameric channel that is expressed on the neuronal membrane. It is formed from different combinations of subunits and is selectively permeable to both Cl\(^-\) and HCO\(_3^-\) ions. The most common configuration is \(\alpha_1\beta_2\gamma_2\alpha_1\beta_2\). The channel is activated by the binding of the neurotransmitter, \(\gamma\)-amino butyric acid (GABA, blue), at the junction between \(\alpha_1\) and \(\beta_2\) subunits. The channel is then opened and allows for Cl\(^-\) (green) and HCO\(_3^-\) (orange) flux down their respective electrochemical gradients in a ratio of 4:1. The benzodiazepines (red) are a class of GABA\(_A\)R allosteric modulators that bind onto the GABA\(_A\)R at the junction of its \(\gamma\) and \(\alpha\) subunits. Under baseline conditions there is typically a low intracellular concentration of Cl\(^-\) (\([\text{Cl}^-]_i\)). B, When GABA\(_A\)Rs are activated, the predominant flux of ions is Cl\(^-\) movement down its electrochemical gradient into the cell. This influx of negative charge causes a membrane hyperpolarisation. C, Benzodiazepines broadly increase the conductance of the GABA\(_A\)Rs by increasing the frequency at which the GABA\(_A\)R opens. This increases the amplitude and duration of the inhibitory postsynaptic potential (IPSP).
CHAPTER 1. INTRODUCTION

1.1.4 The benzodiazepines: a class of GABA<sub>A</sub>R allosteric modulator

Benzodiazepines are a class of synthetic compounds, formed from the union of the benzene and diazepine chemical rings (Müller and Wollert, 1973). By enhancing GABAergic signalling they have anticonvulsant, sedative, hypnotic and anxiolytic properties. The effect of benzodiazepines is determined by the different subunit configurations of the GABA<sub>A</sub>R and their relative distribution throughout the CNS. Furthermore, there are distinct pharmacological profiles for the different benzodiazepine agents including different binding affinities to the different GABA<sub>A</sub>R isoform configurations.

Benzodiazepines bind to the GABA<sub>A</sub>R between its γ and α subunits (Haefely et al., 1993). Specifically, effective benzodiazepine binding onto the α subunit requires a histidine residue (Wieland et al., 1992). This structural requirement for benzodiazepine binding is present in all isoforms of the α subunit except α<sub>4</sub> and α<sub>6</sub> (Duncalfe and Dunn, 1996).

Upon binding, benzodiazepines are able to assert their effects by enhancing the potency of GABA binding (Haefely et al., 1975). This results in an increase in the frequency of channel opening, thereby increasing the conductance of the GABA<sub>A</sub>R. Under typical conditions this facilitates the influx of the negatively charged Cl⁻ ion and enhances membrane hyperpolarisation.

Interestingly, there exists an endogenous equivalent to benzodiazepines known as the enozepines (Costa and Guidotti, 1985; Farzampour et al., 2015). These compounds are released by astrocytes and are also able to positively modulate GABAergic signalling (Christian et al., 2013; Christian and Huguenard, 2013).
CHAPTER 1. INTRODUCTION

The GABA${}_A$R is primarily a Cl$^-$ channel with the effects of its activation being determined by the state of the transmembrane Cl$^-$ gradient. The GABA${}_A$R’s inhibitory function is therefore linked to the transmembrane Cl$^-$ gradient. However, this gradient is dependent on both time and state, fluctuating as a function of development and network activity.

1.2 Chloride dynamics in the brain

1.2.1 Establishing the transmembrane chloride gradient in mature neural tissue

Two membrane cation-chloride co-transporters (CCCs) are primarily responsible for setting the resting neuronal Cl$^-$ gradient [Kaila et al., 2014]. These include the Na$^+$-K$^+$-Cl$^-$ cotransporter (NKCC) and the K$^+$-Cl$^-$ cotransporter (KCC). While there are different configurations of these constructs, NKCC1 and KCC2 are the most prevalent in establishing Cl$^-$ homeostasis in the brain. NKCC1 uses the Na$^+$ gradient to actively pump Cl$^-$ into the cell. Opposing this is KCC2 that uses the K$^+$ gradient to facilitate Cl$^-$ extrusion.

1.2.2 The state of the Cl$^-$ gradient determines the nature of GABA$_A$R function

To fully appreciate GABA$_A$R function, first there needs to be an understanding of how Cl$^-$ ions are directed through the channel [Johnston and Wu, 1995; Raimondo et al., 2017].

Page 13 of 121
CHAPTER 1. INTRODUCTION

The current associated with GABA\textsubscript{A}R activation (\(I_{GABA}\)) is the product of channel conductance (\(g_{GABA}\)) and driving force (\(DF_{GABA}\)) as seen here in Equation 1.1.

\[
I_{GABA} = g_{GABA} \times DF_{GABA}
\]  

(1.1)

The (\(DF_{GABA}\)) is determined by the difference between the membrane potential and the reversal potential for GABA (\(E_{GABA}\)) highlighted in Equation 1.2.

\[
DF_{GABA} = V_m - E_{GABA}
\]  

(1.2)

The reversal potential is defined as the membrane potential where the net ionic current is 0. At this point the movement of ions through the GABA\textsubscript{A}R due to the electric field is matched by the diffusion of ions down their concentration gradient (Raimondo et al., 2015).

During normal baseline activity, the \([\text{Cl}^-]_i\) is typically 5mM and the \([\text{Cl}^-]_e\) 123mM (Raimondo et al. 2013; Ellender et al. 2014). The intracellular concentration of HCO\textsubscript{3}\textsuperscript{-} (\([\text{HCO}_3^-]_i\)) is 15mM and the extracellular concentration of HCO\textsubscript{3}\textsuperscript{-} (\([\text{HCO}_3^-]_e\)) is 24mM (Kaila and Voipio 1987; Kaila et al., 1989). Using these values, the \(E_{GABA}\) (-70.6mV) is calculated by combining the \(E_{\text{Cl}}\) (-80mV) and the \(E_{\text{HCO}_3}\) (-13mV) in a similar ratio to their relative permeability (see Equation 1.3). As previously mentioned (see Section 1.1.3), the GABA\textsubscript{A}R is permeable to both Cl\textsuperscript{-} and HCO\textsubscript{3}\textsuperscript{-} in a ratio of 4:1.

\[
E_{GABA} = \frac{4}{5} \times \frac{RT}{zF} \ln \left[ \frac{[\text{Cl}^-]_e}{[\text{Cl}^-]_i} \right] + \frac{1}{5} \times \frac{RT}{zF} \ln \left[ \frac{[\text{HCO}_3^-]_e}{[\text{HCO}_3^-]_i} \right]
\]  

(1.3)
CHAPTER 1. INTRODUCTION

The state of the \([\text{Cl}^-]\), which may differ in space and time, sets the \(E_{\text{GABA}}\) that then determines the polarity of \(\text{GABA}_\text{A}R\) signalling (Wright et al., 2011). When \(E_{\text{GABA}}\) is negative relative to the resting potential (\(V_m\)), due to a low \([\text{Cl}^-]\), it favours \(\text{Cl}^-\) influx and membrane hyperpolarisation. This reduces the probability of action potential generation and inhibits network excitability. If the \(E_{\text{GABA}}\) were to rise, following an increase in \([\text{Cl}^-]\), it can exceed \(V_m\) but still remain below the action potential threshold. In this state \(\text{GABA}_\text{A}R\) remains inhibitory as the increased \(\text{Cl}^-\) conductance counter-balances the surrounding glutamate-mediated cation influx and thereby prevents further depolarisation towards the AP threshold. This is known as shunting inhibition (Staley and Mody, 1992). However, if the \(E_{\text{GABA}}\) is more positive than the action potential threshold, \(\text{GABA}_\text{A}R\) activation can trigger a spike. When this occurs \(\text{GABA}\)ergic signalling has become excitatory (Staley et al., 1995).

1.2.3 Studying \(\text{GABA}_\text{A}R\) signalling & \(\text{Cl}^-\) dynamics

There are various experimental techniques to elicit \(\text{GABA}_\text{A}R\)-mediated currents. These include the use of exogenous GABA or a selective \(\text{GABA}_\text{A}R\) agonist like muscimol (Forman et al., 2017). In addition, GABA-releasing interneurons can be activated to release endogenous GABA. Traditionally, this has been achieved through electrical stimulation of these \(\text{GABA}\)ergic cells concurrent with glutamate receptor blockade (Ge et al., 2006). More recently however, optogenetic stimulation has allowed for the activation of interneurons either as a group or as individual interneuronal sub-groups. This is achieved by expressing channelrhodopsin (ChR2), a light-sensitive \(\text{Na}^+\) channel, selectively in interneuronal cells (Boyden et al., 2005). When a blue light is then used to activate the opsin, the cells are depolarised and elicit action potentials that then initiate endogenous GABA release at their synaptic targets (English et al., 2012; Ledri et al., 2014).
CHAPTER 1. INTRODUCTION

To explore changes in $[\text{Cl}^-]_i$, a variety of different electrical and imaging tools are available. Imaging techniques include the use of Cl$^-$-sensitive dyes (Kovalchuk and Garaschuk, 2012), or more recently, genetically encoded fluorescent reporters (Grimley et al., 2013; Sato et al., 2017). However, a major limitation of these Cl$^-$ imaging techniques is that they are affected by changes in intracellular pH that are known to fluctuate along with neuronal activity, particularly seizures (Raimondo, Irkle, Wefelmeyer, Newey and Akerman, 2012; Raimondo et al., 2013).

Electrophysiological methods include cell-attached recordings (Tyzio et al., 2008) and perforated patch-clamp recordings (Kyrozis and Reichling, 1995). The main advantage of these techniques is that they are not affected by fluctuations in intracellular pH. Using this technique, $E_{\text{GABA}}$ is measured and the $[\text{Cl}^-]_i$ subsequently calculated using the Nernst equation (see Equation 1.3). Perforated patch-clamp recordings are the predominant technique used in this thesis to measure $[\text{Cl}^-]_i$.

The state of the transmembrane Cl$^-$ gradient can also be manipulated. Traditionally, this has been achieved through genetic or pharmacological manipulation of NKCC2 (Flemmer et al., 2002; Dzhala et al., 2005) or KCC2 function (Hübner et al., 2001; Deisz et al., 2014; Mahadevan and Woodin, 2016; Kelley et al., 2016). However, the more recent development of optogenetic tools has provided a further ability to modulate Cl$^-$ concentration. These include a chloride-specific pump (Raimondo, Kay, Ellender and Akerman, 2012); a chloride-conducting channelrhodopsin (Berndt et al., 2014); an anion-conducting channelrhodopsin (Govornova et al., 2015) and a Cl$^-$ extruder (Alfonsa et al., 2016).

The development of these advanced techniques has allowed scientists to investigate and manipulate Cl$^-$ to explore its role in both development and disease.
1.2.4 Differential expression of CCCs causes long-term plasticity at the GABA synapse

As explained in Section 1.2.2, GABA$_A$R-mediated signalling can be depolarising or excitatory due to increases in $[\text{Cl}^-]_i$. These changes are thought to be driven by changes in the expression patterns of NKCC1 and KCC2 that are relevant in both neurological development and disease (Ben-Ari et al., 2012; Kaila et al., 2014).

In the developing brain, NKCC1 is up-regulated resulting in a higher intracellular concentration of Cl$^-$ (Ben-Ari, 2002). In this state, GABA is depolarising and is thought to be required in order to ‘unsilence’ glutamatergic synapses through the co-activation of NMDA receptors (Wang and Kriegstein, 2008; van Rheede et al., 2015). However, as neural tissues mature there is a down-regulation of NKCC1 which is accompanied by an up-regulation of KCC2 (Rivera et al., 1999). In this mature state, there is increased Cl$^-$ extrusion which results in a lower $[\text{Cl}^-]_i$ and an inhibitory shift in GABA function. This is further illustrated in Figure 1.2.

Figure 1.2 (following page): Cation-chloride co-transporters set the transmembrane chloride gradient. The Na$^+$/K$^+$ ATPase sets the electrochemical gradient of Na$^+$ and K$^+$ across the neuronal membrane. This gradient is then used by the cation-chloride co-transporters, NKCC1 and KCC2, in order to pump chloride in or out of the intracellular space. A, In the developing brain, NKCC1 is upregulated allowing for a higher $[\text{Cl}^-]_i$ and subsequently more positive $E_{\text{GABA}}$ values. In this immature state, GABA$_A$R-mediated signalling is depolarising and can facilitate network excitation. B, As neural tissue matures, there is a down regulation of NKCC1 which is accompanied by an upregulation of KCC2. KCC2 uses the K$^+$ gradient to actively extrude Cl$^-$. In this state, there is a lower $[\text{Cl}^-]_i$, which allows for an inhibitory-shift in GABA$_A$R function as it becomes hyperpolarising. The relative differences in $[\text{Cl}^-]_i$ and corresponding $E_{\text{GABA}}$ values are shown here. This figure was adapted from Blaesse et al. (2009) and Raimondo et al. (2017).
CHAPTER 1. INTRODUCTION

The role of CCCs has also been implicated in various disease states. Here disease-associated changes in the NKCC1 and/or KCC2 expression profile alter inhibitory signalling and overall network function. CCC-induced changes in $[\text{Cl}^-]_i$ has been shown to be involved in the pathophysiology of a growing number of complex disorders (Raimondo et al., 2017). These include autism (Tang et al., 2016), neuropathic pain (Li et al., 2016), schizophrenia (Tao et al., 2012), spasticity (Boulenguez et al., 2010) and, most relevant to this thesis, epilepsy (Huberfeld et al., 2007).

1.2.5 Activity-driven Cl$^-$ plasticity

While CCCs are considered to be a fundamental factor in setting $[\text{Cl}^-]_i$, the state of network activity can also significantly alter the state of the transmembrane Cl$^-$ gradient (Raimondo, Kay, Ellender and Akerman, 2012; Raimondo et al., 2017).

During baseline network activity, $E_{\text{GABA}}$ is typically negative relative to the resting membrane potential ($V_m$). When the GABA$_A$R is activated, the state of the transmembrane gradient favours Cl$^-$ influx causing membrane hyperpolarisation. KCC2 then uses the transmembrane $K^+$ gradient to extrude Cl$^-$. In this state, the inhibitory function of the GABA$_A$R is preserved by maintaining a low $[\text{Cl}^-]_i$ (Staley and Mody, 1992) and low $[K^-]_e$ (Kaila et al., 1997).

An increase in network activity causes an increase in synaptic GABA release and greater GABA$_A$R activation (Staley and Proctor, 1999). This generates more Cl$^-$ influx and a subsequent rise in the $[\text{Cl}^-]_i$. The $E_{\text{GABA}}$ becomes positive relative to the $V_m$ but typically remains below the action potential threshold. In this state, GABA$_A$R-mediated signalling remains inhibitory by counteracting the net effect of the surrounding influx of
cations through shunting inhibition (as explained in Section 1.2.2). The rise in [Cl\textsuperscript{−}]\textsubscript{i} is met by an increase in KCC2 activity in an attempt to re-establish the transmembrane Cl\textsuperscript{−} gradient. This is accompanied by increased K\textsuperscript{+} extrusion and a rise in the [K\textsuperscript{−}]\textsubscript{e} (Kaila et al., 1997).

If network activity increases further, the combined effect of the rising [Cl\textsuperscript{−}]\textsubscript{i} and [K\textsuperscript{−}]\textsubscript{e} soon overwhelms the Cl\textsuperscript{−} extrusion capabilities of KCC2. This increased accumulation of Cl\textsuperscript{−} depolarises \(E_{\text{GABA}}\) above the action potential threshold. In this state, with subsequent GABA\textsubscript{AR} activation, action potentials will be triggered as GABAergic signalling has become excitatory. This short term change in GABA\textsubscript{AR} signalling as a function of a change in the transmembrane Cl\textsuperscript{−} gradient is referred to as short-term ionic plasticity and is further summarised in Figure 1.3.

**Figure 1.3 (following page):** Activity-driven ionic plasticity precipitates a transient excitatory shift in GABA\textsubscript{AR}-mediated signalling. **A,** At rest, there is a low [Cl\textsuperscript{−}]\textsubscript{i} and \(E_{\text{GABA}}\) is hyperpolarised relative to the resting membrane potential (\(V_{\text{m}}\)). This allows Cl\textsuperscript{−} influx and membrane hyperpolarisation. The low [K\textsuperscript{−}]\textsubscript{e} allows for efficient KCC2-mediated extrusion of Cl\textsuperscript{−}. **B,** During states of increased network activity, more GABA is released into the synaptic cleft leading to enhanced GABA\textsubscript{AR} activation. This allows for a greater amount of Cl\textsuperscript{−} influx and rise in the [Cl\textsuperscript{−}]\textsubscript{i}, shifting the \(E_{\text{GABA}}\) to sit above \(V_{\text{m}}\) but remain below the AP threshold. This allows GABA to facilitate shunting inhibition. There is also increased KCC2 activity to try and correct the [Cl\textsuperscript{−}]\textsubscript{i}, which may lead to an increased [K\textsuperscript{−}]\textsubscript{e}. **C,** When hyperexcitability is sustained, \(E_{\text{GABA}}\) depolarises above the AP threshold and GABA\textsubscript{AR} activation becomes excitatory and can trigger APs. The rising [K\textsuperscript{−}]\textsubscript{e} reduces the transmembrane K\textsuperscript{+} gradient which impedes KCC2 function and further facilitates the rise in [Cl\textsuperscript{−}]\textsubscript{i}. This figure is adapted from Viitanen et al (2010) and Raimondo et al (2017).
1.3 Alterations in Cl⁻ dynamics and GABA$_A$R signalling during seizures

1.3.1 Seizures: unregulated hypersynchronous hyperexcitability

Normal neuronal processing is typically characterised by asynchronous firing within neural networks. This regulated activity is formed by excitation being broadly matched by inhibition. However, if inhibitory processes are compromised, an unregulated propagation of hyperexcitability may occur. In this state, network firing becomes hypersynchronous and dysfunctional. This type of aberrant electrical activity is understood to underlie what is referred to clinically as an ictus or seizure. Moreover, the process that leads to this seizure activity is known as ictogenesis (Blauwblomme et al., 2014).

Seizures can manifest clinically in a variety of both convulsive and non-convulsive ways (Fisher et al., 2005). Seizure activity can occur following acute disruptions of the brain (i.e. immediately following trauma) or following systemic disturbances (i.e. metabolic dysfunction). If seizure initiation is unprovoked and recurrent, this clinical presentation is referred to as the neurological disorder of epilepsy. Furthermore, the pathological transition that occurs within the brain to generate unprovoked ictal activity is called epileptogenesis (Goldberg and Coulter, 2013).
CHAPTER 1. INTRODUCTION

1.3.2 Epilepsy: a global health burden

Across the world, epilepsy remains a significant health burden \cite{Salomon2012}. Those affected are severely compromised, both by their seizures and from the side effects of their treatment. While epilepsy remains a global problem, the majority of those who suffer from it reside in resource-poor areas where access to care is limited \cite{Ngugi2011,Newton2012}. There is also a paucity of research describing epilepsy epidemiology and treatment paradigms in this setting \cite{Wilmhurst2014}.

1.3.3 In vitro models of epileptic seizures

In vitro models of epileptic seizures provide a useful means for studying mechanisms underlying seizures and for developing new therapeutic interventions. These in vitro models typically use brain slices which have been prepared acutely (acute brain slices) or slices which have been cultured over a period of days to weeks (organotypic brain slices) \cite{Pitkanen2017}.

Traditionally, various chemo-convulsant paradigms have been used to induce seizure activity using both the above-mentioned brain slice preparations. Disruptions to GABA\(_A\)Rs will readily induce seizure activity. This can be achieved by applying GABA\(_A\)R antagonists such as bicuculline \cite{Griffiths1983,Borck1999} and picrotoxin \cite{Hablitz1984} or by removing [Cl\(^-\)]\(_e\) \cite{Avoli1990}. Other strategies include lowering or elevating the extracellular concentration of various ionic species like Ca\(^{2+}\) \cite{Jefferys1982,Yaari1983}, K\(^+\) \cite{Jensen1988}, or Mg\(^{2+}\) \cite{Anderson1986}. An advantage of the 0 Mg\(^{2+}\) model is that it leaves GABAergic transmission intact. This allows for the study of how the GABA
system might contribute to the evolution and propagation of seizures. This has been demonstrated by Ellender et al (2014) who used a combination of both ionic changes and electrical stimulation to initiate seizure-like events in order to study changes in GABA signalling during seizures.

These in vitro models have allowed for an indepth investigation into the ion dynamics that occur during seizure-like events (Raimondo et al., 2015, 2017). This has largely been achieved using advanced electrophysiology including the use of ion-sensitive electrodes (Dreier and Heinemann, 1991) and perforated patch-clamp recordings (Kyrozis and Reichling, 1995). In addition, recent developments in imaging techniques have allowed for fluctuations in Ca^{2+} (Badea et al., 2001) and Cl⁻ (Raimondo, Irkle, Wefelmeyer, Newey and Akerman, 2012; Sato et al., 2017) to be studied during in vitro epileptiform activity using different biosensors and genetic reporters.

These in vitro models of seizures do have limitations in terms of accurately representing in vivo conditions. However, they have provided an accessible way of studying different aspects of both ictogeneis and epileptogenesis. This includes studying the role GABAergic signalling plays in these processes.

1.3.4 Endogenous anticonvulsant mechanisms

Most seizures are self-limiting in that they stop of their own accord. This is largely due to diverse endogenous anticonvulsant systems that are able to terminate aberrant electrical activity. These systems include sophisticated and potent inhibitory mechanisms that operate at the level of individual neurons and larger networks of neurons (Lado and Moshe, 2008).
CHAPTER 1. INTRODUCTION

The endogenous anticonvulsant mechanisms include pH fluctuations (Chesler and Kaila 1992) as well as glutamate depletion (Staley et al. 1998) and glutamate buffering (Benarroch 2005). In addition, during seizures there appears to be release of various inhibitory neuromodulators including adenosine (Takigawa and Alzheimer 2002; Ilie et al. 2012), endocannabinoids (Lutz 2004; Wallace et al. 2003), neuropeptide-Y (Deborah Lin et al. 2006) and GABA (Wilson et al. 1996). The mechanisms involving the GABAergic system are of particular relevance to this thesis.

Feed-forward and feedback GABAergic transmission is a major endogenous control mechanism for regulating network excitability (Trevelyan et al. 2007). This process is mediated by GABA-releasing interneurons that increase their activity and the release of GABA in response to elevated network activity. In so doing, they provide a significant inhibitory barrier to the spread of seizures.

1.4 The relevance of excitatory GABAergic signalling in seizure activity

Changes in intracellular Cl⁻ dynamics and depolarising GABA have been implicated in the initiation and propagation of seizures. This is summarised in Figure 1.4 and further explained here.
1.4.1 Depolarising GABAergic signalling within the ictal focus is caused by changes in the expression of cation-chloride co-transporters

Within epileptic tissue, there appears to be changes in the expression pattern of CCCs that leads to a depolarising shift in GABAergic signalling. Huberfeld et al (2007) showed this using resected epileptic brain tissue from human patients who had undergone surgery to treat refractory epilepsy. Within this tissue, they noticed that in a significant subset of pyramidal neurons GABAergic signalling was depolarising with this being caused by a down-regulation of KCC2 and a upregulation of NKCC1. This finding suggests that within an epileptic focus, an altered expression of CCCs results in GABAergic signalling becoming permanently depolarising (as illustrated in Figure 1.4, A). These changes in CCCs’ expression appear to be precipitated by neuronal injury either from ischaemia (Pond et al, 2006), trauma (Nabekura et al, 2002) or following recurrent or prolonged seizure activity (Rivera et al, 2004, Pathak et al, 2007, Lee et al, 2010).

To confirm the contribution of these CCCs to seizure activity, in vitro and in vivo studies have used a variety of genetic and pharmacological techniques. Dzhala et al (2005) showed that by blocking the function of NKCC1 with bumetanide, they could drive a negative shift in E_{GABA} as well as reduce epileptiform activity within immature brain tissue. Moreover, Kelley et al (2016) have shown that compromising KCC2 function enhanced the development of seizure activity.

What is clear from this body of work is that long-term changes to Cl⁻ transporters and consequent perturbations of Cl⁻ homeostasis is likely to contribute to the generation of seizures. However, what is somewhat less well studied is how transient changes in [Cl⁻]ᵢ might contribute to the evolution of seizure activity.
1.4.2 Transient Cl⁻ loading occurs during seizure activity

During individual seizures there is a transient depolarising shift in GABAergic signalling (Ilie et al., 2012). This is likely caused by intense GABAₐR activation, Cl⁻ influx and a subsequent increase in [Cl⁻]ᵢ (Raimondo, Kay, Ellender and Akerman, 2012; Ellender et al., 2014; Sato et al., 2017). A representation of these fluctuations is illustrated in Figure 1.4 B. In this state, the activation of the GABAergic interneurons can precipitate after-discharges (Fujiwara-Tsukamoto et al., 2010; Ilie et al., 2012; Ellender et al., 2014). This observation suggests that interneurons may further drive excitation. Importantly, both the [Cl⁻]ᵢ and EₐGABA return to their baseline levels after the seizure activity has terminated with GABAergic signalling resuming its inhibitory function.

Another contributor to this transient, seizure-associated increase in [Cl⁻]ᵢ is the activity of KCC2 (Viitanen et al., 2010). Cl⁻ extrusion is linked to K⁺ extrusion, hence KCC2 activity during seizures leads to elevated [K⁺]ₑ. This then combines with the effect of increased channel-mediated K⁺ efflux to reduce the transmembrane K⁺ gradient. In this state KCC2 extrusion is impaired and precipitates further accumulation of Cl⁻ in the intracellular space.

1.4.3 Implications of depolarising GABAₐR function on seizure dynamics

At the epileptic focus, the above-mentioned changes in CCCs expression and function produce a chronically elevated Cl⁻ state where GABAₐR activation will remain depolarising (as illustrated in Figure 1.4 A). This process is thought to provide a focus for the generation of seizure activity. Surrounding this focus, Cl⁻ extrusion mechanisms are intact and [Cl⁻]ᵢ is maintained at low levels. This helps prevent the propagation
of hyperexcitability beyond the seizure focus. However, under certain conditions the compensatory and intense activation of GABA\textsubscript{A}R signalling leads to a massive influx of Cl\textsuperscript{-} into the intracellular space. This can overwhelm otherwise normal Cl\textsuperscript{-} extrusion mechanisms causing the Cl\textsuperscript{-} transmembrane gradient to collapse, resulting in a loss of inhibitory function. When this inhibitory restraint is compromised, it allows a seizure to propagate freely \cite{Trevelyan2006, Schevon2012}. Furthermore, under these conditions it is possible that compromised GABAergic signalling may also exacerbate the propagation of seizures.

Figure 1.4 (following page): Cl\textsuperscript{-} dynamics during seizure activity. A, In healthy mature neuronal tissue KCC2 is responsible for maintaining a low [Cl\textsuperscript{-}]. In the epileptic focus KCC2 appears dysfunctional or downregulated while NKCC1 is upregulated. This causes a significant increase in [Cl\textsuperscript{-}]. B, A recording trace of a whole-cell patch-clamp recording in voltage-clamp mode (-40mV) showing a 0 Mg\textsuperscript{2+}-induced single seizure-like event from a hippocampal organotypic slice culture. These events are characterised by 4 distinct phases. The pre-ictal period shows an increase in network activity. The tonic phase is characterised by a sudden depolarisation of the membrane accompanied by high-frequency and low-amplitude discharges. The clonic phase is marked by rhythmic bursts or discharges. The post-ictal phase marks the recovery period back to baseline activity. Previous experimental data from both perforated patch-clamp and imaging experiments have shown a transient increase in [Cl\textsuperscript{-}] that occurs during these single seizure-like events that then recovers to baseline when activity is terminated. This is matched by fluctuations in [K\textsuperscript{+}]\textsubscript{e} obtained from extracellular K\textsuperscript{+}-sensitive recordings. C, An illustration of how seizure activity is believed to propagate within the cortex. At the ictal focus both the Cl\textsuperscript{-} and K\textsuperscript{+} gradients are perturbed, however in the surrounding penumbra, they are intact. As seizure activity continues, the surrounding ion gradients are compromised leading inhibition to become dysfunctional. This in turn allows the aberrant ictal activity to propagate. Figure adapted from Raimondo et al \cite{Raimondo2015, Raimondo2017}.
CHAPTER 1. INTRODUCTION

Another important consideration is the possible effect these perturbed Cl\textsuperscript{−} dynamics could have on the anticonvulsant efficacy of pharmacological agents which enhance the activity of GABA\textsubscript{A}Rs, such as the benzodiazepine class of drugs. Previous data from Deeb et al. (2013) has shown that the high [Cl\textsuperscript{−}]\textsubscript{i} that accompanies hyperexcitable states decreases the inhibitory effects of diazepam. Glykys et al. (2015) then showed that the inhibitory efficacy of diazepam correlates with the state of the transmembrane Cl\textsuperscript{−} gradient during development. In addition, Sivakumaran and Maguire (2016) show that when NKCC1 is blocked, diazepam is more effective in reducing epileptiform activity in immature tissue.

Therefore, the effect of disrupted neuronal Cl\textsuperscript{−} on the efficacy of commonly used anticonvulsants which target the GABA\textsubscript{A}R may be particularly relevant in the context of prolonged seizure states such as status epilepticus.

1.5 Status epilepticus & benzodiazepine resistance

1.5.1 Unremitting & self-perpetuating seizure activity

Seizures are typically self-limiting and arrest within a few minutes in adults (DeLorenzo et al., 1992), but in children individual seizures often last slightly longer (Shinnar et al., 2001; Jenssen et al., 2006). Seizure termination is due to many endogenous anticonvulsant mechanisms that can effectively limit ongoing seizure-activity (as discussed in Section 1.3.4). However, under certain conditions, hyperexcitability within the network persists.
CHAPTER 1. INTRODUCTION

Status epilepticus (SE) is the clinical description of enduring and self-perpetuating seizure activity. The recently revised definition now varies across different semiologies with generalised convulsive SE (CSE) being the most common clinical presentation (Trinka et al., 2015). SE is traditionally defined as a seizure persisting for $\geq 30$ minutes. However, it is now appreciated that seizures that do not self-abort within 5 minutes (or recur continuously) are less likely to do so without therapeutic intervention. Therefore, the practical definition of SE is any seizure that is $\geq 5$ minutes in duration or multiple discrete seizures between which there is no extended period of recovery between events.

The prolonged aberrant electrical activity of SE is accompanied by significant morbidity and mortality (Betjemann and Lowenstein, 2015). In adults, mortality associated with convulsive SE is estimated at around 20% (DeLorenzo et al., 1995). This is largely determined by the underlying aetiology, with acute cerebrovascular events and tumours being the most lethal. In children, SE appears to occur more frequently with the most common presentation being prolonged febrile seizures (Chin et al., 2006).

1.5.2 Benzodiazepine resistance in status epilepticus

The current treatment guidelines for SE recommend the use of benzodiazepines as the first line-agents (Trinka et al., 2016). These typically include either diazepam, lorazepam or midazolam with them being equal in their anticonvulsant effect (Alldredge et al., 2001). However, in a subset of patients, mostly children, these agents prove to be ineffective (Appleton et al., 2000). When this occurs second-line agents come with a more severe side effect profile (Chin et al., 2008).

The prevalence of benzodiazepine-resistant SE in children has not been described within a South African context. Therefore, an objective of this thesis was to explore this clinical phenomena in our local paediatric cohort (see Objective 1, Section 1.6.1).
Pharmacoresistant SE has previously been studied using in vitro models, using notably the Mg$^{2+}$-free chemoconvulsant model in both acute [Dreier et al., 1998] and organotypic [Albus et al., 2008] brain slices. In these experiments, a Mg-free aCSF solution is used to promote excitation. From the time the Mg$^{2+}$-free aCSF is washed in, the network shows an evolution from single seizure-like events into a recurrent bursting pattern of activity that has been termed the late recurrent discharge phase (LRD). This LRD phase is thought to be an in vitro replica of the unrelenting hyperexcitability underlying SE.

Using this Mg$^{2+}$-free model, previous data has described a differential effect of benzodiazepines [Zhang et al., 1995, Dreier et al., 1998]. Benzodiazepines appear to retain an anticonvulsant effect if introduced early by delaying the onset of seizure-like events. However, if introduced once LRD had been established, the benzodiazepines failed to show an anticonvulsant effect. A major objective of this thesis was to confirm the effect of benzodiazepine on baseline inhibitory GABAergic signalling in brain slices (see Objectives 2, Section 1.6.1). A subsequent objective was to investigate and quantify differential effects of benzodiazepines on epileptiform activity in the 0 Mg$^{2+}$ model of SE (see Objectives 3 and 4, Section 1.6.1).

In trying understand what may underlie benzodiazepine-resistant SE, it is important to consider the role of GABAergic signalling during these prolonged seizure states.

1.5.3 Changes in GABA$_A$R signalling during status epilepticus

The unremitting aberrant network activity seen in SE is caused by a combination of inhibitory failure as well as the recruitment of processes that facilitate ongoing network excitation [Chen et al., 2007, Betjemann and Lowenstein, 2015]. Specifically, changes in GABA$_A$R transmission are thought to contribute towards SE and will constitute the major focus of this thesis.
CHAPTER 1. INTRODUCTION

Previous data has suggested that after a certain period of ongoing seizure activity, GABA\(_\text{A}\)Rs are internalised (Kapur and Coulter, 1995; Goodkin et al., 2005; Naylor et al., 2005; Goodkin and Kapur, 2009). This would result in a loss of GABAergic inhibitory signalling, which could contribute to both prolonged seizure activity and the loss of benzodiazepine efficacy.

Currently, there is no clear description of how GABAergic signalling might be affected within the early phases of SE. Is GABAergic signalling reduced or does it become excitatory during SE? I will address these question in Objectives 5 and 6 of this thesis (see Section 1.6.1).

1.6 Aims & Objectives

The overall aim of this thesis was to investigate the role of activity-driven excitatory GABAergic signalling on the propagation of prolonged seizures and how this may affect benzodiazepine efficacy.

1.6.1 Objectives

The objectives of this thesis were as follows:

1. To explore the prevalence of benzodiazepine resistance in a local paediatric cohort of patients presenting with SE.

2. To confirm that the anticonvulsant benzodiazepine, diazepam, positively modulates GABA\(_\text{A}\)R-mediated inhibitory signalling.

3. To setup and characterise an established in vitro model of SE using Mg\(^{2+}\) withdrawal in acute and organotypic brain slices.
CHAPTER 1. INTRODUCTION

4. To study the effects of diazepam when applied at different time points in the 0 Mg\(^{2+}\) model of SE.

5. To study changes in GABAergic signalling in the development of prolonged seizure-like states.

6. To investigate activity-driven changes in [Cl\(^-\)]\(_i\).
Chapter 2

Materials and Methods

2.1 Clinical data

The clinical data I present in this thesis was generated by performing an interim analysis on the data being acquired from an ongoing clinical study.

2.1.1 Study design

A randomised and unblinded clinical trial was setup at the Medical Emergency Unit at Red Cross War Memorial Children’s Hospital (RXH) in Cape Town, South Africa. This is an equivalence trial with its main aim being to evaluate the use of two protocols used in the second-line management of paediatric convulsive status epilepticus (CSE). Both protocols (see Appendix A) start with repeated doses of benzodiazepines as first-line management. If the CSE does not terminate after first-line management has been given, patients are then randomised to one of the two second-line management
CHAPTER 2. MATERIALS AND METHODS

protocols. The first protocol recommends the use of repeated doses of intravenous (IV) phenobarbitone. The second protocol recommends IV phenytoin followed by an IV midazolam infusion. This study was approved by the University of Cape Town Human Research Ethics Council (UCT HREC 297/2005).

At admission patients are diagnosed with CSE primarily based on the history given by the patient’s care-givers (or anyone who witnessed the event) along with what is reported by the managing doctor. The definition of CSE includes any convulsive seizure that extends beyond 5 minutes or multiple recurrent convulsive seizures with no return to cognitive baseline in-between events (Trinka et al., 2015). Once the diagnosis is made, patients are randomised to one of the treatment protocols. Randomisation of protocols was done using the online platform, Research Randomizer (Urbaniak and Plous, 2013). As the pharmacokinetic and side-effect profiles of the agents being compared are distinctly different, it is not possible to blind the managing doctor or study investigators from which intervention the patient has been assigned to. After admission, further clinical information is captured retrospectively by reviewing the patient’s hospital folder (obtained from the RXH Medical Records Department).

For this interim analysis, only paediatric patients (under 13 years of age) who presented to the RXH Medical Emergency Department in CSE for the first time were included. Patients readmitted with repeated episodes of CSE were excluded. Furthermore, patients were excluded if they did not meet the clinical definition of CSE, there was a deviation from the treatment protocol or if their clinical records could not be traced.
CHAPTER 2. MATERIALS AND METHODS

2.2 Tissue preparation

In my experiments I used brain slices of the hippocampus and entorhinal cortex prepared from transgenic C57BL/6 mice. These brain areas were chosen due to their significant abundance of GABAergic interneurons (Klausberger and Somogyi 2008; Melzer et al. 2012). Furthermore, both these areas are common epileptogenic foci (Schwartzkroin 1994; Avoli 2007; Kumar and Buckmaster 2006).

Two different preparations of mouse brain tissue were used: organotypic hippocampal slices (organotypic brain slices) and acute hippocampal slices (acute brain slices). The majority of experiments were performed in organotypic brain slices and, where possible, experiments were repeated using acute brain slices. This was done to further validate the results and to limit bias from a single in vitro model (Pitkänen et al. 2017). Due to time and technical restraints, it was not possible to replicate all the experiments in acute brain slices.

2.2.1 Animal tissue

The use of transgenic C57BL/6 in this thesis was approved by the University of Cape Town Research Animal Unit Ethics Committee (project number 014/035). All experiments used a crossed mouse strain on a C57BL/6 background. This strain was a cross between mice expressing cre-recombinase in glutamic acid decarboxylase 2 (GAD2) positive interneurons (GAD2-cre) and mice with a loxP-flanked STOP cassette preventing transcription of the red-fluorescent protein tdTomato (a cre-reporter strain). This created the GAD2-cre-tdTomato strain which exposed the cre-recombinase and tdTomato in all GABAergic interneurons as originally described by Taniguchi et al. (2011). All mice were purchased from Jackson Laboratory (USA).
CHAPTER 2. MATERIALS AND METHODS

All mice used in this thesis were killed by decapitation in accordance with the South African National Standard (SANS10386:2008) and the Veterinary and Paraveterinary Professions Act (Act 19 of 1982). I am a registered member of the South African Veterinary Council (AR14/1327) and am licensed to perform these decapitations. Animal husbandry was provided by the UCT Animal Research Unit.

2.2.2 Organotypic brain slice cultures

Organotypic brain slices were prepared using 7 day old transgenic C57BL/6 mice and followed the protocol originally described by Stoppini et al (1991). Mouse brains were extracted and swiftly placed in cold (4°C) dissection media consisting of Geys Balanced Salt Solution (GBSS #G9779, Sigma-Aldrich, USA) supplemented with D-glucose (#G5767, Sigma-Aldrich, USA). The hemispheres were separated and individual hippocampi were removed and immediately cut into 350 µm slices using a McIlwain tissue chopper (Mickle, UK). Cold dissection media was used to rinse the slices before placing them onto Millicell-CM membranes (#Z354988, Sigma-Aldrich, USA). Slices were maintained in culture medium consisting of 25% (vol/vol) Earles balanced salt solution (#E2888, Sigma-Aldrich, USA); 49% (vol/vol) minimum essential medium (#M2279, Sigma-Aldrich, USA); 25% (vol/vol) heat-inactivated horse serum (#H1138, Sigma-Aldrich, USA); 1% (vol/vol) B27 (#17504044, Invitrogen, Life Technologies, USA) and 6.2 g/l D-glucose. Slices were incubated in a 5% carbon dioxide (CO2) humidified incubator at between 35 - 37°C.

Recordings were made after 6-14 days in culture. Previous studies have shown that after 7 days in culture (equivalent to postnatal day 14) GABAergic signaling and $E_{\text{GABA}}$ has sufficiently developed to a level resembling mature nervous tissue (Streit et al., 1989; Tyzio et al., 2007; Raimondo, Kay, Ellender and Akerman, 2012).
2.2.3 Acute brain slices

Transgenic C57BL/6 mice between 14 to 21 days old were used to prepare acute brain slices. After decapitation, the mouse brain was extracted and quickly placed in a 50% sucrose cutting solution bubbled with carbogen gas (95% oxygen and 5% carbon dioxide). The cutting solution used was composed of (in mM): NaCl (60); KCl (3); NaH$_2$PO$_4$ (1.2); NaHCO$_3$ (23); D-glucose (11); MgCl$_2$ (3); CaCl$_2$ (1) and sucrose (120). pH was adjusted to between 7.38 and 7.42 using 0.1mM NaOH. The mouse brain was then appropriately sectioned using a scalpel blade to ensure that the hippocampus and entorhinal cortex would be sliced in the transverse plane. 400 $\mu$m horizontal slices were cut using a vibrating VF-200 Compressstone® (Precisionary Instruments, USA). This method of preparing acute brain slices is similar to that employed by Dreier et al. [1991, 1998].

For patch-clamp experiments, slices were then transferred to a submerged chamber which contained standard artificial cerebro-spinal fluid (aCSF) and bubbled with carbogen gas. For local field potential recordings, slices were transferred to a custom-built interface chamber [Krimer and Goldman-Rakic, 1997]. The standard aCSF was composed of (in mM): NaCl (120); KCl (3); MgCl$_2$ (2); CaCl$_2$ (2); NaH$_2$PO$_4$ (1.2); NaHCO$_3$ (23); D-Glucose (11) with pH adjusted to be between 7.35-7.40 using 0.1 mM NaOH.

2.2.4 Viral transfection

After 1 day in culture, organotypic brain slices were transfected with adeno-associated vector serotype 1 (AAV1) containing a floxed-STOP channelrhodopsin (ChR2) linked to a yellow fluorescent protein (YFP) tag. The AAV1 has been shown to be effective for viral transfection in organotypic brain slices [Royo et al., 2008].
The AAV1-ChR2-YFP (UNC Vector Core, USA) was then diffusely injected into the organotypic brain slices using a custom-built Openspritzer pressurised ejection device (Forman et al., 2017). 6 days after injection, there was sufficient expression of the ChR2-YFP. Figure 2.1 illustrates this optogenetic paradigm and further highlights how it was used to activate endogenous GABAergic signalling.

---

Figure 2.1 (following page): Using optogenetics to activate endogenous GABAergic signalling. A, Organotypic brains slices were prepared from the GAD2-cre-tdTomato mice and transfected with an AAV1 containing a floxed-STOP ChR2-YFP. This allowed for selective expression of ChR2 in all GABAergic interneurons. Confocal images demonstrate how ChR2-YFP (green) is predominately expressed on the membrane of the GAD2-cre-tdTomato expressing interneurons (red). B, ChR2 is a cation channel that is activated by blue light. Once activated the channel permits cation influx facilitating membrane depolarisation and the generation of action potentials. C, Whole-cell patch-clamp recordings in current-clamp mode from a ChR2-expressing interneuron and a neighbouring pyramidal cell in an organotypic brain slice. Shining blue light (17.1 mW) selectively activates interneurons as shown by how action potentials are generated whenever the light stimulus is present. By contrast, the light stimulus generated hyperpolarising potentials in the pyramidal cell. These are GABAergic postsynaptic potentials.
CHAPTER 2. MATERIALS AND METHODS

A
GAD2-cre-tdTomato
Floxed-STOP
ChR2-YFP

B
Inactive
Active

C
ChR2-expressing interneuron

Pyramidal cell
CHAPTER 2. MATERIALS AND METHODS

2.3 Imaging

The images presented in this thesis were acquired using a confocal microscope (LSM510 Meta NLO, Car Zeiss, Jena, Germany). To visualise tdTomato expression a 561 nm laser was utilised. To visualise YFP-labelled ChR2 a 488nm laser was utilised. In each case, appropriate band pass filters were employed to collect emitted fluorescence.

2.4 Intracellular recordings

2.4.1 Cell visualisation

Brain slices were transferred to the recording chamber where they were continuously superfused with standard aCSF using peristaltic pumps (400D1, Watson-Marlow, UK). Neurons were visualized using a 20X water-immersion objective (XLUMPCFLN-W 20X, Olympus, Japan) or a 40X water-immersion objective (LUMPLFLN 40X, Olympus, Japan) on either a BX51WI upright microscope (Olympus, Japan) or an Axioskop upright microscope (Zeiss, Germany). Digital images of the slices were obtained using a CCD camera (VX55, TILL Photonics, Germany). In acute brain slices, visualization of pyramidal cells was achieved with infrared differential interference contrast microscopy.

2.4.2 Whole-cell recordings

Micropipettes were prepared from borosilicate glass capillaries with an outer diameter of 1.20mm and inner diameter of 0.69mm (Warner Instruments, USA), using a horizontal puller (Intracell Model P-1000, Sutter, USA). When recording GABAergic synaptic currents, pipettes were filled with a high Cl⁻ internal solution (Cl⁻ 141mM) composed of (in mM): KCl (135), NaCl (8.9) and HEPES (10). When recording seizure activity,
pipettes were filled with an internal solution (Cl\textsuperscript{-} 10mM) composed of (in mM): K-glucuronate (120); KCl (10); Na2ATP (4); NaGTP (0.3); Na2-phosphocreatinine (10) and HEPES (10). The pipettes were then placed over a silver wire electrode attached to a CV 203BU head stage (Molecular Devices, USA) which was controlled using motorised micromanipulators (Luigs and Neuman, Germany). Positive pressure was applied and the pipette was lowered onto the surface of the target cell. Once a membrane gigaseal had formed, pipette capacitance was compensated. Break-through was achieved with gentle negative pressure and defined as a drop of access resistance to <20 MΩ. Recordings were made in both current-clamp and voltage-clamp modes using an Axopatch 200B amplifier (Molecular Devices, USA) with data being acquired with either IGOR Pro software (Wavemetrics, USA) or WinWCP (University of Strathclyde, Scotland).

2.4.3 Perforated patch-clamp recordings

To perform gramicidin perforated patch-clamp recordings, I followed the protocol described by Kyrozis and Reichling [1995]. The advantage of this recording technique is that it preserves [Cl\textsuperscript{-}]. Micropipettes were filled with the high Cl\textsuperscript{-} (described in Section 2.4.2). The osmolarity of all internal solutions was adjusted to 290 mOsM and the pH adjusted to 7.38 with NaOH. Gramicidin A (90% pure, Sigma, USA) was dissolved in dimethylsulfoxide (DMSO, Sigma, USA) to achieve a stock solution of 4 mg/ml. Before each recording, a working internal solution was prepared by diluting 5\textmu L of Gramicidin stock in 995\textmu L of the high Cl\textsuperscript{-} internal solution to achieve a final gramicidin concentration of 80\textmu g/ml. The solution was then sonicated and mixed on a rotamixer before being filtered with a 0.45 microm cellulose acetate membrane filter (Merck, USA). Patch pipettes (described in Section 2.4.2) were then back filled with gramicidin working solution. Positive pressure was applied and the pipette was lowered onto the surface of the target cell. Once a membrane gigaseal had formed, pipette capacitance was
CHAPTER 2. MATERIALS AND METHODS

compensated. Adequate perforation of the membrane was assessed by monitoring access resistance and was defined when access resistance was $< 50 \, \text{M}\Omega$. This usually occurred between 10-45 minute after gigaseal had formed. Recordings were made in both current-clamp and voltage-clamp modes using an Axopatch 200B amplifier (Molecular Devices, USA) with data being acquired with WinWCP (University of Strathclyde, Scotland).

Rupture of the gramicidin patch, referred to as a break through, causes massive influx of the high Cl$^{-}$ internal solution into the cell. This causes a significant and permanent increase in the $E_{\text{GABA}}$ at which time recordings would be discarded.

2.4.4 Calculating $\text{GABA}_A$R parameters

In order to study $\text{GABA}_A$R function, $E_{\text{GABA}}$ and $g_{\text{GABA}}$ were calculated. This was achieved by activating $\text{GABA}_A$Rs either with endogenous or exogenous GABA. Endogenous GABA was released by either stimulating ChR2-expressing interneurons with light (in organotypic brain slices), or by electrically stimulating GAD2-interneurons in the presence of glutamate receptor blockade (in acute brain slices). Light stimulus was typically set at 100ms and LED intensity of 17.1 mW. The electrical stimulus was set at 2pA for 3ms. Alternatively, exogenous GABA (#0344, Torcis Bioscience, United Kingdom) was puffed onto the cell using an Opensprizter device (Forman et al., 2017).

In order to calculate resting $E_{\text{GABA}}$ and $g_{\text{GABA}}$, peak $\text{GABA}_A$R currents were elicited at different stepped voltages (a series of 10mV steps above and below a set resting potential of -60mV). Between each recording sweep there was a 10-30s break to allow for adequate recovery of $[\text{Cl}^{-}]$. The peak $\text{GABA}_A$R currents at each voltage were then plotted against the holding potential to generate a current-voltage (I-V) curve. Using this
Chapter 2. Materials and Methods

Graph the resting $E_{\text{GABA}}$ was defined as the x-intercept of the peak GABA$_A$R currents and holding potential. Applying Equations 1.1 and 1.2, $g_{\text{GABA}}$ could be calculated. Furthermore, the $[\text{Cl}^-]_i$ could be calculated from $E_{\text{GABA}}$ by way of the Nernst Equation (see Equation 1.3).

2.5 Extracellular recordings

2.5.1 Local field potentials

For local field potentials, slices were placed in an interface recording chamber (Krimer and Goldman-Rakic, 1997) perfused with aCSF using a peristaltic pump (Model 205S Watson-Marlow, UK). Temperature was adjusted to ensure the solution in the chamber surrounding the slice was kept between 33 - 35°C.

Single-electrode extracellular recordings were performed using patch pipettes (similar to those described in Section 2.4.2) with their tips broken under microscope visualisation using a VT-II 2147861 microscope (Olympus, Japan). Pipettes were filled with Mg$^{2+}$-free aCSF and lowered onto brain slices under microscope guidance. For organotypic brain slices, pipettes were placed in the CA1 region while in acute brain slices they were placed in the entorhinal cortex. Adequate contact was defined by visualising the pipette tip breaking the surface of the perfusing solution above the slice.

Recordings were performed using a 1800 2-Channel Microelectrode AC amplifier (A-M Systems, USA) and associated headstages attached to silver-wire electrodes. Data was acquired using the PowerLab 15T hardware (AD Instruments, New Zealand) and LabChart Pro software package (AD Instruments, New Zealand). Recordings were processed using a digital low-pass filter at 140Hz. During analysis an additional digital high-pass filter at 0.1Hz was applied.
2.6 Seizure models

2.6.1 The 0 Mg\(^{2+}\) chemo-convulsant model

To elicit *in vitro* epileptiform activity, slices were bathed in Mg\(^{2+}\)-free aCSF (Anderson et al., 1986; Mody et al., 1987; Dreier and Heinemann, 1991; Albus et al., 2008). Removing extracellular Mg\(^{2+}\) reduces the voltage dependent block of Mg\(^{2+}\) on N-methyl-D-aspartic acid (NMDA) receptors. When this occurs, the brain slices become predisposed to developing synchronised and sustained hyperexcitability that initially manifests as single seizure-like events (SLEs). Over time this activity then progresses into recurrent epileptiform discharges referred to as the late recurrent discharge (LRD) phase.

2.6.2 Definitions of *in vitro* seizure activity

SLEs recorded using whole-cell patch-clamp recordings were defined as a significant depolarisation (2 standard deviations above the resting membrane potential) that lasted at least 5 seconds while following the typical tonic-clonic pattern (illustrated in Figure 1.4). These were represented as upward deflections in current-clamp mode and downward deflections in voltage-clamp mode. When using extracellular recordings, SLEs were defined as a change in the local field potential that was at least 2 standard deviations away from the baseline activity and lasted for a period of at least 5 seconds.

The LRD phase was defined as recurrent discharges (termed epileptiform discharges) that persist for at least 2 minutes with no return to baseline. This definition was guided by previous *in vitro* work (Zhang et al., 1995; Dreier and Heinemann, 1991; Dreier et al., 1998). Furthermore, as the LRD aims to model clinical SE, this definition aims to align with the revised clinical definition of SE (Trinka et al., 2015).
CHAPTER 2. MATERIALS AND METHODS

Data was excluded from analysis if electrical noise prevented accurate identification of SLEs or LRD. In addition, slices that developed spontaneous seizures prior to being exposed to 0 Mg\(^{2+}\) were also excluded. This was done to prevent any potential kindling process whereby prior seizure activity could alter various properties of the neuronal network, specifically in the GABAergic system. These changes could affect SLE and LRD propensity. (Kamphuis et al., 1991; Morimoto et al., 2004)

2.7 Drugs

Here the various drugs used will be described. Their exact application is explained in greater detail with the relevant experiments presented in Chapter 3.

The following drugs were added to the aCSF solution in the course of various experiments: the GABA\(_A\)R agonist, diazepam (#2805, Torcis Bioscience, United Kingdom); the benzodiazepine competitive antagonist, flumazenil (#1328, Torcis Bioscience, United Kingdom); the GABA\(_B\)R antagonist, CGP-35348 (#1248, Torcis Bioscience, United Kingdom) and the glutamate receptor antagonist, kynurenic acid (#0223, Torcis Bioscience, United Kingdom). Where applicable, the intracellular Na\(^+\) channel blocker QX-314 (#1014, Torcis Bioscience, United Kingdom) was added to the internal solution used to fill patch pipettes.

As diazepam is classified as a schedule 4 restricted substance within South Africa, an import and possession permit was obtained from the South African Medicines Control Council (IMP/123/2016 and Permit No: 033/2016/2017).
2.8 Data analysis

Data analysis was performed using custom written scripts in Matlab (MathWorks, USA). Statistical measurements were performed using GraphPad Prism version 6.0 (GraphPad Software, USA).

For normally distributed numerical data ($p \geq 0.05$, Shapiro-Wilk test), parametric tests were used (i.e. paired or unpaired student’s t-tests). Welch correction was added to unpaired data as I could not assume the standard deviations were the same.

If data was found not to be normally distributed ($p < 0.05$, Shapiro-Wilk test), non-parametric tests were used. For unpaired data this included the Mann-Whitney U test (referred to as Mann-Whitney test) while for paired data the Wilcoxon signed-rank test (referred to as Wilcoxon test) was used.

Categorical data was summarised in contingency tables and differences between groups were identified using the Fisher-exact test.

Significance was defined as a $p$-value $<0.05$. Data is reported as mean $\pm$ standard error of the mean (SEM) unless otherwise stated.

When comparing the effect of diazepam on various manually measured SLE and LRD parameters, data was randomised and the treatment groups blinded by an independent party. Analysis was then performed not knowing which recordings had diazepam added. Data was unblinded only after the statistical analysis was performed. This was done to eliminate any bias introduced by manual analysis of the recordings.
Chapter 3

Results

3.1 Benzodiazepine-resistant status epilepticus is prevalent in a South African paediatric cohort

To give a clinical context to my experimental research, I sought to determine the local prevalence of benzodiazepine-resistant convulsive status epilepticus (CSE). To achieve this, a sample was taken from a cohort of patients that had been recruited into an ongoing clinical trial. The aim of this clinical study is two-fold: (i) to study the epidemiology of CSE in the local paediatric population and (ii) to assess the response to current, unvalidated treatment protocols. However, for the purpose of this thesis, I performed a limited interim analysis to measure the prevalence of benzodiazepine-resistant CSE in a South African paediatric cohort.
CHAPTER 3. RESULTS

At the time this analysis was performed, 144 entries had been loaded into the study (see Figure 3.1 A). 106 (74%) of these had been reviewed while 38 (26%) are still pending review. Moreover, of those patients who’s folders had been reviewed, 13 (12%) were excluded from the study. This was done if the patient either did not satisfy the definition of CSE at admission or if the record of their admission was incomplete (as described in Section 2.1.1). Of the remaining eligible patients, I only analysed their first admission into the study.

As shown in Figure 3.1, of the 73 patients included in the interim analysis, 42% did not respond to first-line benzodiazepine agents that included either diazepam, lorazepam or midazolam given either intravenously (IV) or per rectally (PR). In the sample of the cohort used, 52% were female and 48% males. The median age was 24.95 months with an interquartile range of 38.59 months. Furthermore, there was no significant difference in age between the benzodiazepine-sensitive vs benzodiazepine-resistant patients (42.20 ± 5.64 months vs 33.95 ± 6.58 months, \( p = 0.16 \), Mann-Whitney test). However, when looking at the time between seizure onset and time to delivery of the first-line agent, this was significantly longer in the benzodiazepine-resistant group (45.93 ± 5.45 minutes vs 68.29 ± 8.65 minutes, \( p = 0.018 \), Mann-Whitney test). The median time of seizure duration was 45 minutes with an interquartile range of 52.5 minutes. This suggests that the longer CSE remains untreated the more likely it is to become resistant to benzodiazepines.

This data confirmed that benzodiazepine-resistant CSE is a relevant clinical entity which warrants further investigation into possible cellular mechanisms. This provides the justification for the in vitro research using animal models which follows.
Figure 3.1: Local paediatric prevalence of benzodiazepine-resistant convulsive status epileptics. A, Flow-diagram showing how the data was selected for the interim analysis. B, The proportion of the selected patients who are resistant to first-line treatment with benzodiazepines. C, There was no significant difference in ages between patients in the two groups. D, In the benzodiazepine-resistant group, there was a significantly longer delay from seizure onset to the time the first-line benzodiazepine agent was given. ns = not significant ($p > 0.05$), *$p < 0.05$. 
CHAPTER 3. RESULTS

3.2 Diazepam enhances GABA$_A$R mediated signaling

The aim of these experiments was to confirm that benzodiazepines positively modulate GABA$_A$R-mediated fast synaptic transmission. To achieve this, I performed whole-cell patch-clamp recordings on pyramidal cells whilst eliciting and comparing GABA$_A$R synaptic currents (GSCs) in the presence of the benzodiazepine, diazepam, and its competitive antagonist, flumazenil. I repeated these experiments using two different experimental paradigms.

In the first experiment, I used organotypic brain slices prepared from GAD2-cre-tdTomato mice (as described in Section 2.2.2 and 2.2.4). At day 1 in culture, I injected AAV1 containing floxed-STOP channelrhodopsin (ChR2) into the slices using a custom built pressure ejection system, Openspritzer ([Forman et al., 2017]). After several days in culture, ChR2 was progressively and selectively expressed in the GAD2 expressing interneurons. I then performed voltage-clamp recordings on CA1 pyramidal cells after 6-14 days in culture. To elicit GSCs, I used blue light photoactivation (17.1mW, 100ms) of the ChR2-expressing interneurons to trigger endogenous synaptic release of GABA. Pyramidal cells were voltage-clamped at -40mV in order to increase the Cl$^-$ driving force. Moreover, I used a high Cl$^-$ internal solution (141mM) to artificially load the cell with Cl$^-$. This was done to accentuate GABA$_A$R-mediated signalling. GSCs evoked under these condition generated negative currents that represent Cl$^-$ efflux. In order to prevent the generation of action potentials, I added the intracellular voltage-gated Na$^+$ channel blocker, QX314 (5µM), to the internal solution. In addition, to block the activation of GABA$_B$ receptors, I added CGP55845 (10µM) to the perfusing aCSF solution.
CHAPTER 3. RESULTS

The recording protocol consisted of 30 x 10 second traces in standard aCSF solution. Light stimulation was triggered 2 seconds into each 10 second trace. I then added 3µM diazepam to the aCSF. A 5 minute delay was set before repeating the stimulation protocol. This was done to allow for full perfusion of the submerged chamber with the diazepam-containing solution. Thereafter, in order to reverse any diazepam effect, I washed in aCSF containing the benzodiazepine competitive antagonist, flumazenil (0.4µM) and repeated the same recording protocol. For the analysis, I measured the mean amplitude and time constant (tau). I then compared these metrics across the different treatment groups.

For the second experiment, I prepared acute brain slices from the GAD2-cre-tdTomato mice on the same day of the experiment (see Section 2.2.3). Coronal brain slices including the entorhinal cortex were prepared and I then performed whole-cell recordings on layer V pyramidal cells. To elicit GSCs in these slices, I electrically stimulated the surrounding GAD2-interneurons in the presence of the glutamate-receptor blocker, kynurenic acid (2µM). The same internal solution, blockers and recording protocol was used as described above.
3.2.1 Diazepam enhances the decay time constant, but not the amplitude of light-induced GABA<sub>A</sub>R synaptic currents in organotypic brain slices

In organotypic CA1 pyramidal cells (n = 8), diazepam increased the mean amplitude of the light-induced GSCs compared to baseline (297.70 ± 38.74pA vs 315.00 ± 42.96pA, p = 0.08, paired t-test), however this result was not statistically significant (see Figure 3.2). The application of flumazenil decreased the current size compared to the diazepam group (297.40 ± 38.53pA vs 315.00 ± 42.96pA, p = 0.09, paired t-test) with it showing no difference compared to the baseline GSCs (297.70 ± 38.74pA vs 297.40 ± 38.53pA, p = 0.87, paired t-test).

However, diazepam significantly increased the GSC decay time constant (tau) compared to baseline (43 ± 4 ms vs 57 ± 6 ms, p = 0.004, paired t-test). This was then reversed by the flumazenil (57 ± 6ms vs 40ms ± 4ms, p = 0.005, paired t-test). There was no difference between the time-constants of the baseline and flumazenil groups (43 ± 4ms vs 40 ± 4ms, p = 0.50, paired t-test).

Figure 3.2 (following page): Diazepam enhances the decay time constant but not the amplitude of light-induced GABA<sub>A</sub>R currents in organotypic brain slices. A, Whole-cell patch-clamp recordings (n = 8) from CA1 pyramidal cells in organotypic brain slices. B, During 10s sweeps, GABA<sub>A</sub>R synaptic currents (GSCs) were elicited at 2s by photoactivation (17.1mW, 100ms) of ChR2-expressing interneurons. The mean GSC was calculated from 30 traces in each of the different treatment groups: baseline (B, black), diazepam - 3µM (D, red) and flumazenil - 0.4µM (F, purple). C, Population data of mean GSC amplitudes in each of the treatment groups showing no significant difference between them. D, Deactivation kinetics of GABA<sub>A</sub>R could be fitted by a single exponential function (grey line) to allow for the decay time constant (tau) to be calculated. E, Population data of taus for each group showing that diazepam significantly increased the taus, with this effect being reversed by the application of flumazenil. ns = not significant (p > 0.05), **p ≤ 0.01. DG - dentate gyrus.
CHAPTER 3. RESULTS

A

B

C

D

E

GABA_R current amplitude (pA)

Baseline
+ Diazepam
+ Flumazenil

Time (ms)

Baseline
Diazepam
Flumazenil

Current (pA)

tau = 39ms
tau = 51ms
tau = 38ms

Taus (ms)

ns

ns

ns

100

80

60

40

20

0

B

D

F
CHAPTER 3. RESULTS

3.2.2 Diazepam enhances both the amplitude and the decay time constant of GABA\textsubscript{A}R synaptic currents in acute brain slices

As shown in Figure 3.3 in acute brain slices (n = 8), diazepam significantly increased the amplitude of the electrically-evoked GSCs (216.50 ± 33.58pA vs 350.80 ± 56.00pA, \( p = 0.003 \), paired \( t \)-test). This was then reversed by the application of flumazenil (350.80 ± 56.00pA vs 215.40 ± 31.64pA, \( p = 0.003 \), paired \( t \)-test). There was no difference in amplitude between baseline and flumazenil groups (216.50 ± 33.58pA vs 215.40 ± 31.64pA, \( p = 0.94 \), paired \( t \)-test).

In addition, diazepam lengthened the decay time constant compared to baseline (24 ± 2ms vs 32 ± 3ms, \( p = 0.001 \), paired \( t \)-test) and flumazenil (32 ± 3ms vs 24 ± 2ms, \( p = 0.003 \), paired \( t \)-test). Again, there was no difference between baseline and flumazenil groups (24ms ± 2ms vs vs 24 ± 2ms, \( p = 0.84 \), paired \( t \)-test).

Through these experiments, I was able to confirm that diazepam positively modulates GABA\textsubscript{A}R-mediated synaptic currents in both organotypic and acute brain slice preparations. Furthermore, this effect is reversed by the application of the competitive antagonist, flumazenil.
Figure 3.3 (following page): Diazepam enhances the amplitude and decay time constant of GABA\textsubscript{A}R currents in acute brain slices. A, Whole-cell patch-clamp recordings (n = 7) from layer V pyramidal cells in entorhinal cortex in mouse acute brain slices. B, During 10s sweeps, GABA\textsubscript{A}R currents (GSCs) were elicited by electrical stimulation of afferent fibers (2pA, 3ms) in the presence of the glutamate receptor blocker, kynurenic acid (2\textmu M). The mean GSC was calculated from 30 traces in each of the different treatment groups: baseline (B, black), diazepam - 3\textmu M (D, red) and flumazenil - 0.4\textmu MM (F, purple). C, Population data of mean GSC amplitudes in each of the treatment groups showing a significant increase in GSC size in the presence of diazepam that was then reversed by flumazenil. D, Deactivation kinetics of GABA\textsubscript{A}R currents could be fitted by a single exponential function (grey line) to allow for the time constant (tau) to be calculated. E, Population data of taus for each group showing diazepam significantly increased taus with this effect being reversed by the application of flumazenil. ns = not significant (p > 0.05), **p ≤ 0.01. S - subiculum, MEnt - medial entorhinal cortex, LEnt - lateral entorhinal cortex, DG - dentate gyrus.
CHAPTER 3. RESULTS

A

B

C

D

E

Baseline + Diazepam + Flumazenil

GABA_A current amplitude (pA)

Time (ms)

Current (pA)

Baseline

Diazepam

Flumazenil

$\tau = 31\text{ ms}$

$\tau = 38\text{ ms}$

$\tau = 31\text{ ms}$

ns

** ns

Page 58 of 121
CHAPTER 3. RESULTS

3.3 0 Mg\(^{2+}\) is a reliable \textit{in vitro} model of status epilepticus

To study the effect of diazepam on prolonged seizure states, I first needed to establish a working \textit{in vitro} model of SE. Previous data suggested that the 0 Mg\(^{2+}\) model reliably elicits both single seizure-like events (SLEs) followed by recurrent bursting activity known as the late recurrent discharge (LRD) phase \cite{Zhang1995, Albus2008}. The LRD phase is thought to be an \textit{in vitro} replica of the ongoing unrelenting epileptiform discharges that occurs during SE.

In these experiments, I performed local field potential recordings in organotypic and acute brain slices using an interface perfusion chamber (see Section \ref{section:interface}). The recording protocol would include a 5-10 minute calibration period in standard aCSF, whereafter I would remove Mg\(^{2+}\) from the aCSF (0 Mg\(^{2+}\)). I then noted the differences in SLE and LRD propensity between the organotypic and acute brain slices. In addition, the time delay from when 0 Mg\(^{2+}\) was washed to the onset of SLE and LRD was calculated.

3.3.1 The 0 Mg\(^{2+}\) model elicits prolonged seizure states in both organotypic and acute brain slices

Recordings were made from the CA1 region of organotypic brain slices \((n = 52)\) and entorhinal cortex in acute brain slices \((n = 64)\) (see Figure \ref{figure:3.4}). SLEs were elicited in 79\% of the organotypic brain slices \((n = 41)\) and 64\% of the acute brain slices \((n = 41)\). However, of these slices only 54\% of the organotypic brain slices \((n = 22)\) and 32\% of the acute brain slices \((n = 15)\) continued into the LRD phase. There was no significant difference in SLE propensity \((p = 0.15, \text{Fisher’s exact test})\) or LRD propensity \((p = 0.18, \text{Fisher’s exact test})\) between the different tissue preparations.
CHAPTER 3. RESULTS

Interestingly, organotypic brain slices appear to have SLEs more rapidly compared to acute brain slices ($533.12 \pm 30.09\text{s} \text{ vs } 2183\text{s} \pm 149.70\text{s}, \ p < 0.0001, \ Mann-Whitney \ test$). Moreover, organotypic brain slices go into the LRD phase sooner than acute brain slices ($1365.23 \pm 112.20\text{s} \text{ vs } 5461\text{s} \pm 403.80\text{s}, \ p < 0.0001, \ Mann-Whitney \ test$).

From this data, I was able to confirm that the 0 Mg$^{2+}$ model can reliably elicit prolonged seizure activity in vitro. Furthermore, there appear to be differences in SLE and LRD onset times between the organotypic and acute brain slice preparations.

---

**Figure 3.4 (following page)**: The 0 Mg$^{2+}$ in vitro model of status epilepticus. **A**, Local field potential recording from CA1 in an hippocampal organotypic slice on an interface perfusion chamber. The recording starts with a 10 min calibration in standard aCSF (Std, grey) followed by washing in 0 Mg$^{2+}$ (purple). The time from 0 Mg$^{2+}$ wash in to first seizure-like event (SLE, orange) and entry into the late recurrent discharge phase (LRD, blue) are depicted. **B**, A recording from entorhinal cortex in an acute brain slice. **C**, The organotypic brain slices (black outline) tended to have a higher propensity for SLEs and LRD compared to acute brain slices (grey outline), but this was not statistically significant. **D**, Organotypic brain slices have SLEs sooner and more rapidly enter into the LRD phase compared to acute brain slices. ns = not significant ($p > 0.05$), ****$p \leq 0.0001$. 

Page 60 of 121
CHAPTER 3. RESULTS

A

Std LRD: 1873s 1st SLE: 752s

B

Std LRD: 5933s 1st SLE: 1877s

C

D

Propensity (%) Time (s)
SLE LRD SLE LRD
Organo Acute Organo Acute

n = 52 n = 41 n = 64 n = 41

21% 46% 36% 68%
79% 54% 64% 32%

ns ns

**** ****
CHAPTER 3. RESULTS

3.4 Differential effect of diazepam on the 0 Mg$^{2+}$ in vitro model of status epilepticus

Having established a working 0 Mg$^{2+}$ model of SE, I then sought to study the effect of diazepam on these prolonged seizure states. In order to extend data from previous studies (Zhang et al., 1995; Dreier et al., 1998; Albus et al., 2008), the aim of these experiments was to investigate the effect of diazepam on the evolution of seizure activity in the 0 Mg$^{2+}$ model using organotypic brain slices.

To achieve this, I setup three different experimental paradigms (see Figure 3.5). The first was a control group ($n = 13$) where after the 5-10 minute calibration period 0 Mg$^{2+}$ was washed in. The second, the early group ($n = 10$), included washing in diazepam (3\,\mu M) with the 0 Mg$^{2+}$. The third, the late group ($n = 9$), only introduced diazepam after LRD was established. Various properties of epileptiform activity were measured including the time to SLE onset, SLE duration, the frequency of SLEs prior to entry into the LRD phase and the time to the onset of the LRD phase. In addition, a 60 second window of LRD activity was analysed. This window was taken at a standard point across all three groups, exactly 7 minutes after the onset of LRD. This includes the 2 minutes of ongoing bursting activity to confirm entry into the LRD phase (Section 2.6.2). Furthermore, a 5 minute delay was then added to accommodate full perfusion of the interface chamber with a new solution. This was relevant to the late group when diazepam was only introduced after initiation of the LRD phase. Within these 60 second windows, I then measured the discharge duration, frequency and inter-discharge interval.
CHAPTER 3. RESULTS

For the analysis, I only included recordings if they did not have any SLEs during the 5-10 minute calibration period. Furthermore, recording needed to display SLEs followed by LRD. Traces where only SLEs or LRD existed were not included. Importantly, in order to eliminate any possibility of bias introduced during the analysis, the experimental traces were randomised and I was blinded to which treatment group they belonged to (as explained in Section 2.8).

3.4.1 Early application of diazepam has a significant anticonvulsant effect while late application augments bursting activity in the LRD phase

As illustrated in Figures 3.5 and 3.6, when diazepam is introduced early, it significantly delayed the onset of SLEs compared to the control (522.15 ± 45.93s vs 799.73s ± 89.81s, \( p = 0.003 \), Mann-Whitney test) and late groups (548.8 ± 34.46s vs 799.73 ± 89.81s, \( p = 0.008 \), Mann-Whitney test). Moreover, washing diazepam in early significantly decreased SLE duration compared to control (21.04 ± 1.69s vs 14.57 ± 1.66s, \( p = 0.013 \), unpaired t-test) and late groups (27.41 ± 2.72s vs 14.57 ± 1.66s, \( p = 0.001 \), unpaired t-test). Furthermore, there was a significant decline in SLE frequency before entry into the LRD in the early group compared to control (10.85 ± 1.66 vs 5.00 ± 3.06, \( p = 0.01 \), unpaired t-test) and late groups (11.33 ± 1.78 vs 5.00 ± 3.06, \( p = 0.005 \), unpaired t-test). There was no difference between the control and late groups in SLE onset (522.15 ± 45.93s vs 548.8 ± 34.46s, \( p = 0.50 \), Mann-Whitney test), duration (21.04 ± 1.69s vs 27.41 ± 2.72s, \( p = 0.07 \), unpaired t-test) or frequency (10.85 ± 1.66 vs 11.33 ± 1.78, \( p = 0.85 \), unpaired t-test). Taken together this demonstrates that diazepam has a significant anticonvulsant effect on the 0 Mg²⁺ model when it is applied early.
CHAPTER 3. RESULTS

In terms of entry into the LRD phase, in the early group there was a significant delay vs the control ($1429 \pm 187.1 \text{s}$ vs $2623 \pm 513.9 \text{s}$, $p = 0.03$, Mann-Whitney test) and late groups ($1274 \pm 169.2 \text{s}$ vs $2623 \pm 513.9 \text{s}$, $p = 0.0004$, Mann-Whitney test). Within the defined 60 second analysis windows, there was a significant increase in discharge duration between both the control versus early ($2.42 \pm 0.41 \text{s}$ vs $4.44 \pm 0.68 \text{s}$, $p = 0.02$, Mann-Whitney test) and late groups ($2.42 \pm 0.41 \text{s}$ vs $4.72 \pm 2.62 \text{s}$, $p = 0.02$, Mann-Whitney test). Furthermore, there was a significant decrease in discharge frequency in the 60 second window between control versus the early ($12.92 \pm 1.77$ vs $7.10 \pm 1.52$, $p = 0.0005$, Mann-Whitney test) and late groups ($12.92 \pm 1.77$ vs $7.44 \pm 0.99$, $p = 0.01$, Mann-Whitney test). There was no difference between early and late groups in either discharge duration ($4.44 \pm 0.68 \text{s}$ vs $4.72 \pm 2.62 \text{s}$, $p = 0.81$, unpaired t-test) or frequency ($7.10 \pm 1.52$ vs $7.44 \pm 0.99$, $p = 0.76$, unpaired t-test). Although it is not shown in Figure 3.6, there was no significant difference in the inter-discharge interval between the control and the early ($5.20 \pm 0.72$ vs $6.00 \pm 1.05$, $p = 0.51$, Mann-Whitney test) or late groups ($5.20 \pm 0.72$ vs $6.56 \pm 0.88$, $p = 0.25$, Mann-Whitney test). These findings suggest that the presence of diazepam once LRD has been established does not reduce epileptiform activity. On the contrary, diazepam increases the duration of discharges without affecting the inter-discharge interval.

From these experiments I have demonstrated that diazepam has a differential effect on evolution of epileptiform activity using the 0 Mg$^{2+}$ model depending on whether it is applied ‘early’ or ‘late’.
CHAPTER 3. RESULTS

Figure 3.5 (following page): Differential effect of diazepam on the 0 Mg\(^{2+}\) model of status epilepticus in organotypic brain slices. A, Control experiment where 0 Mg\(^{2+}\) was washed in after a 5-10 minute calibration period. Time to SLE onset (orange) and entry into the LRD phase (blue) are marked. B, Early application of diazepam (3\(\mu\)M) introduced when 0 Mg\(^{2+}\) is washed in. C, Late group where diazepam only washed in after the LRD phase had been established. Windows \(t_{1-3}\) highlight individual SLEs shown in Figure 3.6, A. Windows \(t_{4-6}\) highlight 60s of LRD used for analysis as shown in Figure 3.6, E.
CHAPTER 3. RESULTS

A

0 Mg²⁺

Std

0 Mg²⁺

1708s

560s

30s

60s

B

0 Mg²⁺ + 3uM DZP

Std

2250s

809s

30s

60s

C

0 Mg²⁺

Std

0 Mg²⁺ + 3uM DZP

1518s

512s

45s

60s
CHAPTER 3. RESULTS

Figure 3.6 (following page): Population data showing the differential effect of diazepam on the 0 Mg\(^{2+}\) model of status epilepticus in organotypic brain slices. The data in this figure follows from the experimental paradigms presented in Figure 3.5. 

A, \(t_{1-3}\) showing individual SLEs from the control \(t_1\), early \(t_2\) and late groups \(t_3\). 

B, Population data showing that early introduction of diazepam delays SLE onset whilst decreasing SLE duration, C, and frequency before entry into the LRD phase, D. E, \(t_{4-6}\) marking the 60 second windows used to analyse LRD activity in the control \(t_4\), early \(t_5\) and late groups \(t_6\). 

F, Population data showing that diazepam delays onset of LRD in the early group. The presence of diazepam in the early and late groups increases discharge duration, G, while decreasing discharge frequency, H. ns = not significant \((p > 0.05)\), \(* p \leq 0.05\), \(** p \leq 0.01\), \(*** p \leq 0.001\).
3.5 GABAergic signalling is strongly depolarising during the late recurrent discharge phase

Previously in this Chapter (see Section 3.2), I showed that diazepam positively modulates GABA_{A}R-mediated signalling. Having now shown that diazepam has a differential effect on the evolution of \textit{in vitro} SE (see Section 3.4), I then focused on exploring changes in the properties of GABA_{A}R-mediated signalling during these states. While previous work has confirmed a transient excitatory shift in GABA_{A}R function during single SLEs \cite{Ilie2012, Ellender2014}, to date there is no data confirming whether this may still be relevant in the LRD phase which models SE.

3.5.1 Optogenetic activation of interneurons drives excitatory signalling in the evolution of prolonged seizure states

Using the same optogenetic paradigm described in Section 3.2, I performed whole cell recordings on CA1 pyramidal cells in organotypic brain slices ($n = 7$). Voltage-clamp was used with cells clamped at -40mV using a standard internal solution (see Section 2.4.2). The ChR2 expressing GAD2-interneurons were then activated every 7s with 100ms of blue-light illumination. After 3 minutes of recording in standard aCSF, 0 Mg\textsuperscript{2+} was washed in and SLEs and LRD allowed to develop. After at least 5 minutes of LRD, I then reintroduced standard aCSF in an attempt to arrest the LRD phase. Only traces with both SLEs and LRD were included in the analysis.
RESULTS

In order to study changes in the light-induced currents, I used a combination of both automated and manual detection methods to measure the size and direction of these currents. Figure 3.7 demonstrates the experimental protocol using current-clamp. Figure 3.8 then shows the same protocol in voltage-clamp with population data highlighting the changes in light-induced currents. The light-induced currents are an unspecified combination of both GABA$_A_R$, GABA$_B_R$ and possibly disynaptic glutamate receptors.

There was a significant positive shift in the direction of light-induced currents during a single SLE, $t_2$, vs baseline, $t_1$ (448.80 ± 70.34pA vs -752 ± 88.67pA, $p =0.0002$, paired t-test). This would recover after the SLE had self-terminated. There was a significant change in the currents during SLE recovery, $t_3$, versus those seen during the after-discharge phase of the SLE, $t_2$ (-752.00 ± 88.67pA vs 536.50 ± 134.90pA, $p =0.0007$, paired t-test). Furthermore, light-induced currents during the LRD phase, $t_4$, were significantly more depolarising compared to recovery after the single SLE, $t_3$ (536.50 ± 134.90pA vs -894.00 ± 164.80pA, $p =0.0018$, paired t-test). After reintroduction of Mg$^{2+}$-containing aCSF and termination of LRD, the currents again became significantly hyperpolarising, $t_6$, compared to those observed during the LRD phase, $t_4$ (-894.00 ± 164.80pA vs 242.00 ± 21.21pA, $p =0.0005$, paired t-test). There was no significant difference in amplitude between induced currents during SLE, $t_2$, and LRD, $t_4$ (-752.00 ± 88.67pA vs -894.00 ± 164.80pA, $p =0.18$, paired t-test). However, the light-induced currents appear significantly smaller after recovery from LRD, $t_6$, compared to baseline, $t_1$ (242.00 ± 21.21pA vs 448.80 ± 70.34pA vs, $p =0.04$, paired t-test).
3.5.2 Prolonged seizure activity leads to a significant decrease in light-induced GABAergic conductances

In comparing the amplitude of the light-induced currents before and after seizure activity (see Figure 3.9), there was a significant decrease between baseline ($t_1$) and recovery ($t_6$) ($448.80 \pm 70.34\text{pA}$ vs $242.00 \pm 21.21\text{pA}$, $p = 0.04$, \textit{paired t-test}). Furthermore, step protocols performed before baseline and after recovery (see Figure 3.7) show a significant decrease in conductance in the light-induced currents ($17.79 \pm 5.93\text{nS}$ vs $12.37 \pm 5.18\text{nS}$, $p = 0.02$, \textit{Wilcoxon test}). Importantly, there was no change in access resistance ($15.50 \pm 1.87\text{m}\Omega$ vs $17.12 \pm 5.91\text{m}\Omega$, $p = 0.13$, \textit{paired t-test}) nor in membrane potential ($-58.75 \pm 2.22\text{mV}$ vs $-59.37 \pm 2.36\text{mV}$, $p = 0.19$, \textit{paired t-test}). This confirms that the observed decrease in current amplitude and conductance was not as a consequence of the whole-cell recording deteriorating over time.

\textbf{Figure 3.7 (following page)}: Transient shifts in the effect of GABAergic interneurons during the evolution of prolonged seizure activity. \textit{A}, Current-clamp recording from a CA1 pyramidal cell in an organotypic slice with photoactivation of ChR2-expressing GAD2 interneurons (100ms every 7s at 17.1mW). After 3 minutes of recording in standard aCSF (Std, grey), 0 Mg$^{2+}$ aCSF (purple) was washed in. After at least 5 minutes of late recurrent discharge (LRD) activity, standard aCSF was washed in. The boxes labelled ($t_{1-6}$) mark 30 second windows of the trace. \textit{B}, Expanded view of the $t_{1-6}$ windows. $t_1$ is taken from baseline, $t_2$ during the after-discharge phase of a single seizure-like event (SLE), $t_3$ recovery after single SLE, $t_4$ cut-out of activity during LRD, $t_5$ during recovery in standard aCSF showing sudden change in size and direction of light-induced currents and $t_6$, a cut-out of activity when the slice had fully recovered in standard aCSF.
CHAPTER 3. RESULTS

Figure 3.8 (following page): Activation of GAD2 interneurons results in depolarising currents in pyramidal cells during single and prolonged seizures. A, Voltage-clamp recording from a CA1 pyramidal cell in an organotypic slice clamped at -40mV. Photoactivation of ChR2-expressing GAD2 interneurons (17.1mW, 100ms) occurred every 7 seconds. After 3 minutes of recording in standard aCSF (Std, grey), 0 Mg$^{2+}$ aCSF (purple) was washed in. After at least 5 minutes of late recurrent discharge (LRD) activity, standard aCSF was again washed in. The boxes labelled $(t_{1-6})$ mark 30 second windows of the trace. B, Expanded view of the $t_{1-6}$ windows where $t_1$ is taken from baseline, $t_2$ is taken during the after-discharge phase of a single seizure-like event (SLE), $t_3$ is taken during recovery after single SLE, $t_4$ is a cut-out of activity during LRD, $t_5$ is taken during recovery in standard aCSF showing sudden change in size and direction of light-induced currents and $t_6$ is a cut-out of activity when the slice had fully recovered in standard aCSF. C, Population data showing significant changes in current size and direction across the different time intervals $t_{1-4}$ and $t_6$. *$p \leq 0.05$), **$p \leq 0.01$, ***$p \leq 0.001$. 

Page 73 of 121
CHAPTER 3. RESULTS

A

B

C
CHAPTER 3. RESULTS

Figure 3.9 (following page): Changes in baseline GABAergic signalling before and after prolonged seizure activity. A, Whole-cell voltage-clamp recording from a CA1 pyramidal cell in an organotypic brain slice clamped at -60mV using an internal solution containing 10mM of Cl⁻. A voltage step protocol was followed starting at -100mV and ending at -40mV progressing in 10mV increments. At 1 second after each voltage step, ChR2-expressing GAD2 interneurons were activated with 100ms of blue light (17.1mW). The grey dotted line marks the holding current at each step. The red dotted line marks the GABA currents elicited by photoactivation. The baseline (black) was taken before 0 Mg²⁺ wash in (before $t_1$ in Figures 3.7 and 3.8). The recovery (blue) was taken after the network had fully recovered from LRD (after $t_6$ in Figures 3.7 and 3.8). B, A current-voltage (IV) plot showing intersection of baseline and light-induced currents at different holding voltages. Reversal potential for the light-induced GABA current $E_{GABA}$ is marked by the black arrow. C, Population data showing no difference in $E_{GABA}$ between baseline and recovery. D, There was a significant difference in conductance of the light-induced GABA current in the recovery phase compared to baseline. There was no difference in access resistance, $E$, or membrane potential, F, between the step protocols in the baseline and recovery groups. ns = not significant ($p > 0.05$), ***$p \leq 0.001$. 

Page 75 of 121
3.6 Synchronised activation of GAD2 interneurons entrains network activity during the LRD phase through GABA_A signalling

In previous experiments (see Figures 3.7 and 3.8), I show how photoactivation of GAD2 interneurons drives strongly depolarising currents during the LRD phase. I then noted that the epileptiform discharges that occur during the LRD could be elicited by photoactivation of interneurons (see Figure 3.10). During a 5 minute analysis period taken from the LRD phase, I analysed traces in 7 second frame windows, with light activation occurring 3.5 seconds into the 7 second window. This 7 second window was then divided into smaller 200 millisecond time bins whereby the probability of an epileptiform discharge being initiated could be calculated.

I observed that the probability of eliciting a discharge increased to $0.78 \pm 0.06$ during the 200 milliseconds immediately following light application. Furthermore, the probability of the being in a discharge increased for several seconds following light-activation. This suggests that optogenetic activation of GAD2 interneurons entrains the hippocampal network during the LRD phase.
CHAPTER 3. RESULTS

Figure 3.10: Photoactivation of GAD2 interneurons significantly increases discharge probability in the LRD phase. A, Whole-cell voltage-clamp recording from a CA1 pyramidal cell in an organotypic slice clamped at -40mV (same trace seen in Figure 3.9). Cut-out is of a 60s window of LRD showing discharges being initiated by photoactivation. B, Population data from 7 slices. Left axis (black, histograms with ± SEM) represents the probability of a discharge being initiated in any given 200 millisecond time bin within a 7 second window from a 5 minute LRD analysis period. The right axis (blue, line plot with ± SEM) represents the probability of a discharge being present at the time of photoactivation.
3.6.1 Synchronised activation of GAD2 interneurons is responsible for entraining the hippocampal network during the LRD phase

To provide further evidence to support that this entrainment is indeed due to photoactivation of GAD2 interneurons, I then performed a control experiment to compare discharge probability before and after photoactivation (see Figure 3.11). To do this, I switched on the light only after a minimum of 5 minutes of LRD activity had occurred. The discharge probability at the point the light was switched on significantly increased (0.06 ± 0.02 vs 0.53 ± 0.09, $p = 0.002$, paired t-test).

Figure 3.11 (following page): Network entrainment follows photoactivation of GAD2 interneurons during the LRD phase. A, Whole-cell voltage-clamp recording from a CA1 pyramidal cell in an organotypic brain slice clamped at -40mV. This trace represents a 10 minute window from the onset of LRD. $t_1$ and $t_2$ are 60 second windows of activity before and after photoactivation (17.1mW, 100ms) was initiated. B, Population data ($n = 7$) from the 5 minute analysis window showing the probability of a discharge initiation in 200 millisecond time bins (black, histograms with ± SEM) as well as the probability of a discharge occurring at any point during the 7 second window (blue, line plot with ± SEM). C, Population data showing the mean change in discharge and event probability after photoactivation was initiated. D, Graph highlighting how discharge probability significantly increases when the blue light is switched on.
CHAPTER 3. RESULTS

A

B

C

D
3.7 Blocking the GABA$_A$R reverses network entrainment via optogenetic activation of GAD2 interneurons

Lastly, to test whether excitatory GABA$_A$R signalling was responsible for these light-induced discharges, I added the GABA$_A$R blocker, picrotoxin (100uM), to the perfusing aCSF after at least 5 minutes of LRD activity (see Figure 3.12). The picrotoxin did not arrest the LRD activity. However, I did note that the discharge probability following the light stimulus decreased significantly ($0.64 \pm 0.08$ vs $0.08 \pm 0.03$, $p = 0.03$, Wilcoxon test).

Figure 3.12 (following page): The GABA$_A$R antagonist, picrotoxin, decreased network entrainment by photoactivation of GAD2 interneurons. A, A whole-cell voltage-clamp recording from a CA1 pyramidal cell in an organotypic brain slice clamped at -40mV. This trace is a 10 minute window from the onset of LRD with light-stimulus (100ms) every 7 seconds. After at least 5 minutes of LRD activity, picrotoxin (100µM) was washed in. $t_1$ and $t_2$ are 60a windows of activity before and after picrotoxin (orange) was washed in. B, Combined graph of population data ($n = 6$) from the 5 minute analysis window showing the probability that photoactivation initiates a discharge (black, histograms with ± SEM) and the probability of a discharge bring present is shown in blue (line plot with ± SEM). C, Population data showing the mean change in discharge and event probability after picrotoxin was washed in. D, Graph highlighting how discharge probability significantly decreased in the time bin following when the blue light was switched on in 0 Mg$^{2+}$ versus when picrotoxin had been added (orange). **$p \leq 0.01$. 
CHAPTER 3. RESULTS

A

B

C

D
CHAPTER 3. RESULTS

3.7.1 The frequency of epileptiform discharges during the LRD phase is affected by synchronised activation of GAD2 interneurons

In the previous experiments (see Figures 3.10, 3.11 and 3.12), I showed how photoactivation GAD2 interneurons can entrain the hippocampal network. I then noted that this entrainment could affect the frequency of epileptiform discharges. This is illustrated in Figure 3.13 (A) where it appears that within a 5 minute analysis period, whenever photoactivation occurs (‘LED on’), 30% of the discharges follow the frequency at which the light stimulus is activated (0.14 Hz). In comparison, if the light is off (‘LED off’) or picrotoxin is present (Px) there is a wider distribution of frequencies at which the discharges occur.

This was then confirmed by calculating the difference between the frequency at which the light was activated and the frequency of discharges within the 5 minute analysis window (see Figures 3.13 B). This difference is smaller in the ‘LED on’ group compared to the ‘LED off’ group (0.04 ± 0.02 vs 0.12 ± 0.03, p =0.03, Mann-Whitney test) and Px (0.04 ± 0.02 vs 0.12 ± 0.02, p =0.04, Mann-Whitney test) groups. Taken together, this suggests that the frequency at which the recurrent epileptiform discharges occur during the LRD phase can be mediated by optogenetic activation of GABAergic signalling.
Figure 3.13: Synchronised photoactivation of GAD2 interneurons and blocking of the GABA$_A$R affects epileptiform discharge frequency during the LRD phase. **A**, Cumulative percentage plot showing the distribution of discharge frequencies across the three groups, control with no photoactivation (LED off, $n = 7$), photoactivation (LED on, $n = 7$) and photoactivation with 100µM picrotoxin washed in (Px , $n = 6$). Grey lines mark x1 and x2 the frequency of the light stimulus (0.14Hz and 0.28Hz). **B**, Population data showing the difference between frequency of photoactivation (x1 grey line in A) and the observed frequency of discharges within a 5 minute analysis window. In the LED on group, this difference is significantly smaller when compared to the LED off and Px groups. ns = not significant, *$p \leq 0.05$. 
CHAPTER 3. RESULTS

3.8 Studying activity-driven changes in intracellular Cl-
concentration

As GABA$_A$Rs are largely permeable to Cl$^-$, I used the gramicidin perforated patch-clamp technique to measure the $E_{GABA}$ without perturbing the $[Cl^-]_i$ (see Section 2.4.3 and 2.4.4). Once a gigaseal has been achieved, gramicidin perforates the cell membrane with cation-specific pores. While this gives electrical access to the cell, the gramicidin does not permit the passage of Cl$^-$ and thereby maintains the transmembrane Cl$^-$ gradient.

In order to measure $E_{GABA}$, I activated the GABA$_A$R in one of two ways (see Section 2.4.4). First, GABA (100µM) was puffed on the soma using a pressure ejection system. Alternatively, ChR2-expressing GAD2 interneurons where stimulated with blue light to trigger the release of endogenous GABA. A voltage step protocol similar to that seen in Figure 3.9 was then used to generate IV plots. These were then used to calculate the $E_{GABA}$. I then used the Nernst Equation (Equation 1.3) to calculate the $[Cl^-]_i$. The $[Cl^-]_e$ I used for solving the Nernst equation was the Cl$^-$ of the standard aCSF solution (123mM).

3.8.1 Both endogenous and exogenous GABA application can be used to determine the intracellular concentration of Cl$^-$ in organotypic brain slices

As illustrated in Figure 3.14 by combining the data from the puffed and light-stimulated GABA ($n = 16$), I was able to calculate a mean $E_{GABA}$ of -80.80 ± 2.39mV from which I was able to calculate a mean $[Cl^-]_i$ of 5.65 ± 0.53mM.
It is worth noting that the [Cl\(^-\)] in the internal solution was 141 mM which is much higher than the calculated [Cl\(^-\)]\(_i\). This indicates that it is likely that the integrity of the gramicidin perforated patches were well maintained. Furthermore, there was no difference in conductance of the GABA currents elicited by exogenous (\(n = 10\)) vs endogenous (\(n = 6\)) GABA stimulation (11.39 ± 2.28nS vs 7.07 ± 0.69nS, \(p = 0.07\), Wilcoxon test). Although not shown in the Figure 3.14 I observed no difference in membrane potential (-70.65 ± 1.91mV vs -63.74 ± 3.12mV, \(p = 0.21\), Wilcoxon test) or access resistance (65.09 ± 4.67Ω vs 48.77 ± 7.66Ω, \(p = 0.07\), Wilcoxon test) between the two different methods.

**Figure 3.14 (following page):** Exogenous application of GABA versus optogenetic stimulated GAD2-interneurons to determine intracellular concentration of Cl\(^-\) in organotypic brain slices. 

**A**, Gramicidin perforated patch voltage-clamp recordings from CA1 pyramidal cells clamped at -60mV. The recording protocol included voltage steps in increments of 10mV above and below -60mV. During each voltage step, either exogenous GABA (100µM) was puffed onto the soma or ChR2-expressing GAD2 interneurons were stimulated with a light impulse (100ms, 17.1mW). Grey line marks the holding current for each step while the red line marks the current elicited by either the exogenous application or endogenous release of GABA. **B**, Current-voltage (IV) plots showing GABA current reversal potential (\(E_{\text{GABA}}\)) calculated at the point where the GABA current and the holding current intersect. **C**, Population data of \(E_{\text{GABA}}\) values obtained using both methods. **D**, Estimated [Cl\(^-\)]\(_i\) concentrations calculated from \(E_{\text{GABA}}\) values using the Nernst equation (Equation 1.3). **E**, There was no difference in GABA current conductance elicited by exogenous GABA or ChR2-activated interneurons. ns = not significant.
CHAPTER 3. RESULTS

3.8.2 Transient, activity-driven changes in intracellular Cl\(^-\) occur during single seizure-like events

In this final experiment, I aimed to confirm the transient, activity-driven changes in \([\text{Cl}^-]_i\) that were observed during single SLEs as previously described by Ellender et al (2014). As illustrated in Figure 3.15, I performed a perforated patch-clamp recording in a CA1 pyramidal cell from an organotypic brain slice. The recording protocol alternated between current and voltage-clamp modes. In voltage-clamp a ramp protocol would then start starting at -90mV and continuing until -20mV. The ramps were repeated twice within 1.5 seconds. During the second ramp a GABA conductance was elicited by exogenous puffs of GABA on the soma in order to determine \(E_{\text{GABA}}\) at that point.

Seizures were elicited using the 0 Mg\(^{2+}\) model. At the start of a single SLE standard aCSF containing 2mM Mg\(^{2+}\) was washed in. This was done to terminate the seizure and allow for accurate measurement of the \(E_{\text{GABA}}\) that would otherwise be compromised by ongoing spiking activity during the after-discharge phase. From the ramp protocols, IV plots could be drawn and the estimated \(E_{\text{GABA}}\) and \([\text{Cl}^-]_i\) calculated.

Before the onset of a SLE \((t_1)\), I measured the \(E_{\text{GABA}}\) to be -65.81mV equating to a \([\text{Cl}^-]_i\) of 9.50mM. However, during the after-discharge phase of the SLE \((t_2)\), both the \(E_{\text{GABA}}\) and \([\text{Cl}^-]_i\) rose to -36.22mV and 30.04mM respectively. Once the cell had recovered \((t_3)\), the \(E_{\text{GABA}}\) and \([\text{Cl}^-]_i\) returned to pre-SLE values (-65.24mV and 9.71mM). This is in keeping with what had been reported by Ellender et al (2014).
CHAPTER 3. RESULTS

Figure 3.15 (following page): Transient Cl\textsuperscript{-} loading occurs during a single seizure-like event. 

**A**, Using a gramicidin perforated patch-clamp recording, the $E_{GABA}$ was measured at different stages of a single seizure-like event (SLE). During recording the mode was rapidly switched between current-clamp (CC - 8 seconds) and voltage-clamp (VC - 1.5 seconds). In voltage-clamp, two ramp protocols were applied in quick succession of each other. During the second ramp, GABA (100µM) was puffed onto the cell soma. 

**B**, Representative trace from a CA1 pyramidal cell from a hippocampal organotypic slice. SLEs were elicited using the 0 Mg\textsuperscript{2+} model. At SLE onset, 2mM Mg\textsuperscript{2+} aCSF was washed in to block ongoing spiking activity. $E_{GABA}$ measurements are marked by blue circles and were sampled prior to SLE onset ($t_1$), during the after-discharge phase ($t_2$) and at recovery ($t_3$). 

**C**, Ramp protocols taken each of the time points, $t_{(1-3)}$. 

**D**, IV plots were drawn and extrapolated to estimate $E_{GABA}$ values. The [$Cl$]$_i$ was then calculated using the Nernst equation (Equation 1.3)
CHAPTER 3. RESULTS

A
CC → VC (8s) → CC (1.5s) → CC (8s)

- GABA
GABA (100 µM)

800 pA
4250 ms
250 ms

B
0 Mg²⁺
2mM Mg²⁺

E_{GABA} (mV)
-30
0
30
60
90

E_{GABA} (mV)
-30
0
30
60
90

C

D

E_{GABA} = -65.81 mV
[Cl⁻] = 9.50 mM

E_{GABA} = -36.22 mV
[Cl⁻] = 30.04 mM

E_{GABA} = -65.24 mV
[Cl⁻] = 9.71 mM
Chapter 4

Discussion

In this final chapter I will discuss the relevance of the major clinical and experimental findings that have been presented in this thesis. Where appropriate, I will highlight shortcomings in the methodology and propose avenues for future research.

4.1 Benzodiazepine-resistant status epilepticus is prevalent within our local paediatric population

The clinical data I have presented in this thesis (see Section 3.1), confirms that within our local paediatric cohort, 42% of patients who present in CSE do not respond to first-line treatment with benzodiazepines. I then noticed, that this group of patients appear to have significantly longer episodes of CSE before receiving treatment.
These findings are similar to what has been reported in a larger British study by Chin et al (2008). In their cohort, 187 patients received benzodiazepines as first-line intervention, with 35% not responding to this treatment. Furthermore, they showed that patients who require more than 2 doses of benzodiazepines have a significantly higher risk of going into respiratory depression, a life-threatening complication of benzodiazepine treatment. This suggests that failure to respond to first-line treatment with benzodiazepines is associated with increased morbidity in paediatric patients.

A major limitation of the clinical data presented in this thesis is that it is incomplete. It represents an interim analysis of an ongoing clinical study. A more in-depth analysis is still to be performed in order to identify potential characteristics that may separate out the benzodiazepine-resistant group. This will include studying differences in past medical history, underlying aetiology, semiology, pre-hospital treatment as well as immediate and long-term outcomes.

Despite this clinical data being limited, it was ultimately successful in achieving its modest objective. I was able to confirm that benzodiazepine-resistant SE is a relevant clinical entity within our paediatric population. This has provided a suitable introduction to my experimental investigation into how changes in GABAergic signalling may be relevant to benzodiazepine resistance in SE.
4.2 Diazepam modulates GABA\(_A\)R synaptic currents during normal network activity

In Figures 3.2 and 3.3 I showed how diazepam positively modulates GABA\(_A\)R synaptic currents (GSCs). I then demonstrated how this can be reversed using the competitive antagonist, flumazenil. These findings are similar to what has been described by Deeb et al. (2013) who used dissociated cell cultures and elicited GSCs using exogenous application of the GABA\(_A\)R agonist, muscimol.

Interestingly, my data seems to suggest that there is a difference in the effect of diazepam on GSCs between the organotypic and acute brain slices. In the organotypic brain slices diazepam has a more subtle effect by only affecting the decay constant and not the amplitude of the GSCs. By contrast, in the acute brain slices diazepam the effect is more impressive, affecting both the amplitude and decay constant of the GSCs.

This finding may be explained by inherent differences between the two brain slice preparations. In organotypic brain slices, previous work by Mckinney et al. (1997) has shown that during the preparation of these slices there is significant damage to the structural integrity of the neural network, mainly in the form of axonal injury. When these neurons are maintained in culture, axonal sprouting occurs that leads to recurrent connections being formed between neurons. This causes an overall increase in network excitability (Dyhrfjeld-Johnsen et al., 2010). The full extent of how this aberrant network activity affects synaptic transmission, and specifically the distribution and configuration of GABA\(_A\)Rs, is still unknown. Future experiments may aim to provide further insight into this by studying GABA\(_A\)R subunits in the organotypic brain slices using various antibody-labelling and advanced imaging techniques.
CHAPTER 4. DISCUSSION

Other important technical differences to consider include the method of activating GABA_AAR signalling as well as the brain area recorded from. Ideally, I would have preferred using optogenetics in both slice preparations. However, due to technical limitations this was not possible in acute brain slices. Moreover, it is also unknown if GABAergic signalling is different between the CA1 (organotypic) and layer 5 of entorhinal cortex (acute). For this reason, these experiments should be repeated in equivalent cell populations in both slice preparations.

Lastly, another limitation was that only one benzodiazepine (diazepam) at one dose (3µM), was studied. This dose was chosen as it had previously been shown to be effective by Deeb et al (2013). Future experiments could aim to study the effect of different types and doses of benzodiazepines on GSCs.

4.3 The 0 Mg^{2+} model provides a reliable in vitro replica of status epilepticus

Using the Mg^{2+} model, I demonstrated how SE-like activity could be induced in both organotypic and acute brain slices (see Figure 3.4). In both tissue preparations, the introduction of the Mg^{2+} solution precipitated an increase in slice activity that then progressed first into single SLEs followed by entry into a phase of recurrent epileptiform discharges, known as the LRD phase. These findings are consistent with previous in vitro studies [Dreier and Heinemann 1991, Zhang et al. 1995, Dreier et al. 1998, Pal et al. 1999, Deshpande et al. 2008, Albus et al. 2008, Kelley et al. 2016]. Therefore, I have furthered validated that this a reliable model in which to study the evolution of prolonged seizure activity in vitro.
Interestingly, there appear to be a significant difference in the SE-like activity between the different tissue preparations. While there was no significant difference in SLE or LRD propensity, in the organotypic brain slices SLE and entry into LRD appears to occur sooner compared to the acute brain slices.

Organotypic brain slices, by themselves, are considered to be a model of post-traumatic epileptogenesis and have been shown to generate spontaneous seizure activity while in culture (Dyhrfjeld-Johnsen et al., 2010). The trauma caused by the slicing procedure in combination with keeping them in culture causes aberrations within the neural circuitry, as well as widespread cell death (Coltman et al., 1995; Simoni et al., 2003; Berdichevsky et al., 2012). The consequence is sustained hyperexcitability within these slices which may explain why there is faster onset of seizure activity in the organotypic brain slices compared to acute brain slices.

A limitation of my data set is that I only studied a single pro-convulsant model. There is a difference in patterns of seizure activity between the various in vitro seizure models, and this may prove to be relevant when studying SE-like activity. For example, Albus et al. (2008) describe distinct differences in the types of seizures generated by the 0 Mg$^{2+}$ model compared to using the K$^+$ channel blocker, 4-aminopyridine (4-AP), to elicit seizure activity. Furthermore, Kelley et al. (2016) have demonstrated that the 4-AP model generates repeated SLEs, but never enters into the LRD phase. These differences between models need to be appreciated as they may significantly alter the reproducibility of results. Furthermore, these differences may bias the understanding of underlying ictogenesis as well as the observed sensitivity to anticonvulsants.
4.4 Diazepam has a differential and time-dependent effect on in vitro status epilepticus

Having setup the 0 Mg$^{2+}$ model in organotypic brain slices, I then showed how diazepam affects the development and progression of prolonged seizure activity (see Figures 3.5 and 3.6).

When introduced early, diazepam appears to delay the onset of SLEs while also making them shorter and occur less frequently. However, it did not seem to prevent the progression into the LRD phase nor was it able to ablate SE-like activity. Interestingly, I then noticed that the presence of diazepam in the early part of the LRD phase appears to positively modulate the recurrent epileptiform discharges. Notably, diazepam increased the duration of discharges without affecting the inter-discharge duration. The results from these experiments demonstrate how in the 0 Mg$^+$ model, diazepam is first anticonvulsant and then progresses to enhancing epileptiform activity.

Albus et al (2008) show a comprehensive study of the effect of various anticonvulsants on organotypic brain slices using the 0 Mg$^{2+}$ model and therefore provide a useful reference to compare findings. Interestingly, their use of diazepam (at higher doses of 5µM and 35µM) also failed to prevent SLE onset and shortened SLEs. However, their data was not statistically significant nor did they look at the effect of diazepam on other LRD parameters like discharge duration and frequency.

A limitation of my results is the particular analysis approach used. Currently, the analysis of LRD activity was limited to discrete 60 second window at a predefined time point early in the LRD period (7 minute after onset). A more accurate method of assessing the effect of diazepam on the LRD activity would be to employ a fully automated approach whereby the individual discharges are detected and analysed across
CHAPTER 4. DISCUSSION

A much longer time window. In addition, the effect of diazepam on the amplitude and power (using a fast fourier transform) should be performed (Glykys and Staley 2015). Moreover, future experiments could analyse the effect of diazepam on LRD activity at different time intervals to identify if and when the activity becomes truly pharmacoresistant and can no longer be positively modulated by benzodiazepines.

Another limitation is that these experiments have only been conducted in organotypic brain slices. Therefore, to increase the validity of these results the experiments should be repeated in acute brain slices. Given the impressive effect of diazepam on baseline GABAAR signalling (as shown in Figure 3.3), it will be interesting to see how diazepam may affect seizure activity in this preparation.

Despite these limitations, taken together with my data showing how diazepam positively modulates the GABAAR (see Section 4.2), these findings suggest that enhancing this receptor’s function during the LRD phase positively modulates the epileptiform discharges. This implies that the GABAAR-signalling may participate in SE-like activity.

4.5 GABAergic signalling drives epileptiform discharges during in vitro status epilepticus

4.5.1 GABAergic signalling is excitatory in both single seizures and SE-like activity

In the development of prolonged seizure states, I have shown how GABAergic signalling shifts between being inhibitory and excitatory (see Figures 3.7 and 3.8). This extends previous in vitro work by showing that excitatory GABAergic signalling is also present during the LRD phase (Ilie et al. 2012, Ellender et al. 2014).
My findings appear to contrast what has been proposed by Ledri et al (2014) as they had previously shown that the activation of GAD2 interneurons is able to suppress SLEs. However, there are important differences in methodology that may explain this. Importantly, there is a significant difference in the stimulation protocol they used as they found the most significant suppressant effect to occur when the light was activated for prolonged periods of at least 5 seconds. When they only stimulated for 1 millisecond, this suppressant effect was lost, which is consistent with what I found when I only stimulated for 100 milliseconds. Taken together, a possible explanation is that prolonged activation of the interneurons, which are believed to be excitatory during the seizure, may push them into a period of depolarising block whereby they are no longer able to participate in the propagation epileptiform activity.

In this work I activated the entire interneuronal population by using ChR2 expression driven by the GAD2 promoter. However, it may be interesting to determine how the different subpopulations of interneurons might contribute to SE-like activity. For example, a recent study by Khoshkhoo et al (2017) has shown that the various classes of interneurons contribute differently to the initiation and propagation of seizures. Specifically, using an in vivo model of induced seizures, they show that the parvalbumin (PV) and somatostatin (SS) interneurons appear to contribute towards maintaining seizure activity. This is consistent with my own data and with what is proposed by Ellender et al (2014), who have shown that synchronised activation of PV interneurons can trigger afterdischarges during individual SLEs. Interestingly, Khoshkhoo et al (2017) also show that vasoactive intestinal-peptide (VIP) interneurons are involved in curtailing seizure activity. As these interneurons primarily target the other two interneuronal subpopulations, they could be viewed as silencing the excitatory activity of PV and SS interneurons.
CHAPTER 4. DISCUSSION

4.5.2 GABAergic signalling is reduced after prolonged seizure activity

After showing that excitatory GABAergic signalling plays an active role in SE-like activity, I then showed that there is a significant reduction in the conductance of the light-activated GABAergic signalling before and after these prolonged seizures (see Figure 3.9). This finding is consistent with previous data that shows how SE-like activity causes an internalisation of the GABA_ARs leading to a decrease in its inhibitory function (Goodkind et al., 2005; Naylor et al., 2005).

Taken together with the data I have shown in Figures 3.5 and 3.6, this suggests that the integrity of GABAergic signalling changes as the LRD phase is allowed to progress. Early in this SE-like activity, GABA_ARs may remain intact which would explain how diazepam is able to modulate the duration of epileptiform discharges. However, over time the prolonged seizure activity drives endocytosis and recycling of GABA_ARs (Goodkin et al., 2005), and may reduce their ability to contribute towards seizure activity. It is therefore assumed that at a certain point the epileptiform discharges will no longer be sensitive to diazepam. In order to confirm this, further research is needed into how diazepam affects LRD activity at different time points (as proposed in Section 4.4).

4.5.3 Photoactivation of GABAergic signalling entrains SE-like activity through the GABA_ AR

After demonstrating that GABAergic signalling is excitatory during the LRD phase, I then showed that by controlling GABAergic signalling I am able to alter the probability of when the recurrent epileptiform discharges occur (Figure 3.10). Furthermore, if a discharge was not elicited by the activation of the GAD2 interneurons, I found that the network was more likely to already be within a discharge and therefore refractory to subsequent activation.
CHAPTER 4. DISCUSSION

I then confirmed this observation by showing a significant difference between before and after photoactivation was initiated (Figure 3.11). Thereafter, I showed how this entrainment of the LRD activity is mediated by the GABA$_A$R as washing in picrotoxin was able to disrupt this effect (see Figure 3.12). Interestingly, the GABA$_A$R antagonist was not able to ablate epileptiform discharges, which suggests that they can be generated by alternate mechanisms, most likely glutamatergic signalling.

In Figure 3.13 I then showed that by modifying GABAergic signalling, I was able to alter the frequency of epileptiform discharges during the LRD phase. With synchronised activation of the GABAergic interneurons I was able to entrain the frequency of the discharges around the frequency of the light stimulus. By contrast, when the light is off or the GABA$_A$R is blocked, there is a wider distribution of discharge frequencies.

Taken together, these results suggest that GABAergic interneurons and specifically GABA$_A$R signalling can precipitate epileptiform discharges during SE-like activity. However, GABA$_A$R signalling is not solely responsible for generating epileptiform discharges.

Interestingly, previous work confirms that GABAergic interneurons and specifically GABA$_A$R signalling can precipitate epileptiform discharges during SE-like activity. However, GABA$_A$R signalling is not solely responsible for generating epileptiform discharges.

Interestingly, previous work confirms that GABAergic signalling is involved in the LRD phase, however in an opposing way. Dreier et al (1991) have shown that washing in picrotoxin accelerates the frequency of discharges during the LRD phase. When the picrotoxin was then accompanied with the GABA$_B$R agonist, baclofen, they noticed a marked decrease in discharge frequency. By contrast, Albus et al (2008) report that washing in muscimol during the LRD phase reduces the seizure activity which seems to suggest that GABA$_A$R-mediated signalling is inhibitory. These experiments used somewhat crude pharmacological manipulation of the GABAergic system during SE. Nonetheless, this lack of consensus justifies further research into investigating how GABA$_A$R-mediated signalling participates in generating and maintaining the epileptiform discharges during the LRD phase.
4.6 Seizure-induced changes in Cl$^-$

4.6.1 Using optogenetics to elicit GABAergic inhibitory signalling

While performing perforated patch-clamp recordings, I was able to demonstrate that using optogenetic activation of GABAergic interneurons is an effective way of eliciting GSCs in order to measure $[\text{Cl}^-]_i$ (see Figure 3.14). This complements previous work by Raimondo et al (2012) and further shows how optogenetics can be used to study synaptic inhibition as well as to study $[\text{Cl}^-]_i$ dynamics.

4.6.2 Transient, activity-driven changes in intracellular Cl$^-$ during single-seizures

In my final experiment (see Figure 3.15), I successfully replicated the results of Ellender et al (2014). Indeed, I showed that GABAergic signalling does become excitatory during the after-discharge phase of single SLEs and this is related to an increase in $[\text{Cl}^-]_i$. Furthermore, these seizure-induced Cl$^-$ dynamics have also been imaged using advanced Cl$^-$ genetic reporters (Raimondo, Irkle, Wefelmeyer, Newey and Akerman, 2012; Sato et al., 2017).

This suggests that maintaining Cl$^-$ homeostasis is important in limiting seizure activity. Alfonsa et al (2015) have demonstrated that by inducing Cl$^-$ loads using the light-activated Cl$^-$ pump, halorhodopsin, they were able to increase network excitability. Furthermore, Alfonsa et al (2016) then developed a novel optogenetic Cl$^-$ extruder, Cl-out, that is able to remove Cl$^-$ from the intracellular space and in doing so, delay the propagation of ictal activity.

While the role of these Cl$^-$ dynamics have been shown to occur during single seizures, their relevance during SE-like activity is still to be confirmed.
4.7 General discussion

In this final section, I will broadly conceptualise how changes in GABA\(_A\)R function and structure are responsible for benzodiazepine resistance. I do this by situating the findings of my thesis within the context of existing literature. I have further summarised these thoughts in Figure 4.1.

The main finding of my thesis is that excitatory GABA\(_A\)R-mediated signalling plays an active part in positively modulating the recurrent epileptiform discharges that characterise an in vitro replica of SE-like activity. Having confirmed that during single SLEs, this excitatory GABAergic signalling is linked to a transient increase in \([Cl^-]_i\), I postulate that this short-term ionic plasticity may also be present during prolonged seizure activity (see Figure 4.1, A). If this is proved to be true, benzodiazepines would be an ineffective anticonvulsant to treat SE and by enhancing excitatory GABAergic signalling, may further propel this unrelenting seizure activity.

In order to confirm this link, further research is needed to study Cl\(^-\) dynamics during the LRD using either perforated patch-clamp recordings or Cl\(^-\) imaging techniques. Another way of confirming this would be to try and reduce \([Cl^-]_i\) during the LRD phase using the optogenetic Cl\(^-\) extruder, Cl-out (Alonsa et al., 2016). It would be interesting to see if this would be able to reverse the excitatory shift in GABAergic signalling, as well as rescue the anticonvulsant effect of benzodiazepines.

Impaired KCC2 function has also been implicated in prolonged seizure activity (see Figure 4.1, B). Kelley et al. (2016) showed that by blocking KCC2 with VU0463271 or knocking it out (using the S940A point-mutant mouse) they were able to accelerate entry into the LRD phase. It is postulated that the increased \([Cl^-]_i\) that results from poor KCC2-mediated Cl\(^-\) extrusion would drive excitatory GABAergic signalling and render benzodiazepines ineffective.
Finally, SE-driven GABA$_A$R trafficking and remodeling needs to be considered (see Figure 4.1 C). As already discussed (see Section 1.5.3), during SE the GABA$_A$R undergoes an endocytosis-mediated internalisation. Once internalised, there can be a reconfiguration of GABA$_A$R subunits which typically involves a replacement of the $\alpha_1$ and $\gamma_2$ subunits (needed to form the benzodiazepine binding-site) with $\alpha_5$ and $\delta$ subunits (Friedman et al., 1994; Rice et al., 1996). This reconfigured GABA$_A$R no longer possesses a benzodiazepine binding-site, and instead is preferentially re-expressed in the extrasynaptic space. This is likely to represent a more long-term effect (hours to days) which could also explain benzodiazepine resistance to SE.

In summary, changes in Cl$^-$ dynamics and GABA$_A$R expression may provide an explanation for how the seizure activity becomes resistant to benzodiazepines. Understanding how these mechanisms relate to each other is a fertile ground for future study.
CHAPTER 4. DISCUSSION

Figure 4.1: Disruptions to GABA\(_A\)R structure and function may be responsible for benzodiazepine-resistant status epilepticus. **A**, Activity-driven intracellular accumulation of Cl\(^-\) and extracellular K\(^+\) (short-term ionic plasticity). **B**, Long-term or short-term KCC2 dysfunction allow for [Cl\(^-\)]\(_i\) to rise, leading to an excitatory shift in GABA\(_A\)R function. **C**, During SE, the GABA\(_A\)R undergoes an endocytosis-mediated internalisation. Once in the intracellular space the subunits are reconfigured with subunits insensitive to benzodiazepines. The refurbished GABA\(_A\)R is preferentially redistributed outside the synaptic cleft.
CHAPTER 4. DISCUSSION

4.8 Concluding remarks

In the course of this thesis I have demonstrated that benzodiazepine-resistant SE is prevalent within our South African paediatric population. I have showed how benzodiazepines have a differential and time dependent effect on an \textit{in vitro} model of SE. My data also demonstrates that excitatory GABAergic signalling plays an active role in driving epileptiform activity during SE and is likely to represent part of the explanation for benzodiazepine resistance in SE. Relating my findings to dynamic changes to the transmembrane Cl\textsuperscript{−} gradient during SE is a pertinent topic for future research.

Taken together the work presented in this thesis may inform the design and choice of optimum pharmacological strategies for treating SE.
Bibliography


BIBLIOGRAPHY


BIBLIOGRAPHY


Shepherd, G. M. (2003), The synaptic organization of the brain, 5 edn, Oxford University Press.


BIBLIOGRAPHY


Appendix A

Appendix

A.1 Protocols for treating paediatric status epilepticus

Included here are the management protocols used by Medical Emergency Unit at Red Cross War Memorial Children’s Hospital for the treatment of paediatric status epilepticus (SE). Patients recruited into the above-mentioned clinical study are randomly allocated to one of the two protocols.

Both protocols use repeated doses of benzodiazepines as first-line management. Thereafter, in one protocol a patient will then receive repeated doses of phenobarbitone. This is the preferred clinical practice, however, the use of phenobarbitone for paediatric SE is not recognised by the Medicines Control Council (MCC) of South Africa. By contrast, if allocated to the other protocol, after not responding to the benzodiazepines the patient will receive phenytoin followed by a midazolam infusion. This is the current recognised practice for managing paediatric SE in South Africa.
APPENDIX A. APPENDIX

PATIENT RECRUITMENT FORM

Project: Childhood Convulsive Status Epilepticus – in search of optimal drug treatment
UCT HREC # 297/2005

In managing this patient's status epilepticus, please strictly follow the treatment protocol illustrated below and complete the required form that follows.

[Diagram showing patient recruitment form with steps and drug dosages]

STEP I
- IV Lorazepam preferred intervention
- LORAZEPAM 0.5mg/kg IV or MEDAZOLAM 0.2mg/kg IV or DIAZEPAM 0.3mg/kg IV
- Still convulsing after 3 - 10 minutes

STEP II
- LORAZEPAM 0.5mg/kg IV or MEDAZOLAM 0.2mg/kg IV or DIAZEPAM 0.3mg/kg IV
- Still convulsing after 5 - 10 minutes
- Insert IV / IO line

STEP III
- PHENOBARBITONE 20mg/kg IV
- Still convulsing after 3 - 10 minutes
- Flush line afterwards

STEP IV
- PHENOBARBITONE 10mg/kg IV
- Still convulsing after 3 - 10 minutes
- Flush line afterwards

STEP V
- PHENOBARBITONE 10mg/kg IV
- Still convulsing after 5 - 10 minutes
- Discuss management with senior / ICU
- Recheck glucose & consider antibiotics

STEP VI
- Additional work-up and management of underlying cause & complications as per standard practice for the individual child

If patient has a high fever,
- Give child with room temperature water
- Do not give oral medication until the convulsion has been controlled

Directions for administering rectal Diazepam
- Draw up dose into 1ml syringe and remove the needle
- Place child in the recovery position
- Insert the syringe 4 - 5cm into the rectum and inject the solution
- Hold buttocks together for a few minutes

Please stick patient sticker here
# APPENDIX A. APPENDIX

## PATIENT RECRUITMENT FORM

**PHENYTOIN & MIDAZOLAM**

Project: Childhood Convulsive Status Epilepticus – in search of optimal drug treatment  
**UCT HREC # 297/2005**

In managing this patient's status epilepticus, please strictly follow treatment protocol illustrated below and complete the required form that follows.

<table>
<thead>
<tr>
<th>Step</th>
<th>Treatment Options</th>
</tr>
</thead>
</table>
| **Step I** | IV Line preferred intervention  
**YES**  
LOPAZEM 0.1mg/kg IV or MIDAZOLAM 0.15mg/kg IV or DIAZEPAM 0.2mg/kg IV  
| **NO**  
**STEP I** | IV Line preferred intervention  
LOPAZEM 0.1mg/kg IV or MIDAZOLAM 0.15mg/kg IV or DIAZEPAM 0.2mg/kg IV  |
| **Step II** |  
**START IV IN 10 MINUTES**  
PHENYTOIN  
20mg/kg IV slowly over 30min  
(Mu ± 10 ml of 0.9% NaCl only)  
ECG monitoring  
| **SNM consulting after 3 - 10 minutes** |
| **Step III** |  
MIDAZOLAM  
0.2mg/kg IV (bolus) followed by re-bolus 0.5mg/kg 0.25 at 1 - 4 minute intervals  
| **SNM consulting after 3 - 10 minutes** |
| **Step IV** |  
Discuss management with senior ICU  
Re-check glucose & consider antibiotics  
**Step V** |  
Additional work-up and management of underlying cause / complications as per standard practice for the individual child  

*If patient has a high fever:*  
Sponge child with warm tepid water  
Do not give oral medication until the convulsion has been controlled

**Directions for administering rectal Diamorphine:**  
Clean up down into 1ml syringe and evacuate needle  
Place child in the recovery position  
Infiltrate the syringe 0.5 - 1cm into the rectum and insert the solution  
Hold buttocks together for a few minutes

---

Please stick patient sticker here